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ABSTRACT  
 
The importance of improving people's quality of life has aroused the interest of the food 
industry to develop new products with functional characteristics that may be associated 
with possible beneficial effects on human health, either preventive or therapeutic aspects. 
Functional foods and nutraceuticals present in its composition bioactive substances that 
provide medical benefits and, therefore, have aroused the interest of many consumers 
around the world. Mushrooms are a source of proteins, vitamins, minerals, and especially 
bioactive compounds. These compounds, including ergosterol, phenolic compounds, 
tocopherols, ascorbic acid and carotenoids, have been associated with antioxidant, anti-
inflammatory, antimicrobial and cytotoxic properties, among others attributed to 
mushrooms and associated to its promoting health effects. Following this approach, the 
present work aimed to develope nutraceutical formulations based on mycelium of Agaricus 
bisporus L. and Pleurotus ostreatus (Jacq. Ex Fr.) P. Kumm. The present study highlights 
the potential of in vitro culture as a tool to improve production of bioactive compounds by 
two different mushroom species. Accordingly, A. bisporus and P. ostreatus were studied 
for their composition in phenolic acids and sterols, antioxidant activity (DPPH radicals 
scavenging, reducing power, β-carotene bleaching inhibition and TBARS formation 
inhibition), anti-inflammatory effect (by down-regulating LPS-stimulated NO in 
RAW264.7 cells) and cytotoxic activity (using MCF-7, NCI-H460, HeLa, HepG2 and 
PLP2 cell lines). Therefore, the mycelia of A. bisporus and P. ostreatus was cultured in 
different solid and liquid media, and further submitted to solid-liquid extraction processes; 
these assayed species showed differences in the growth rate and yielded biomass. Overall, 
P. ostreatus mycelia showed higher contents of ergosterol and phenolic compounds (but 
the mycelia of A. bisporus produced in PDA presented a higher amount of p-
hydroxybenzoic acid) and stronger antioxidant activity than the corresponding fruting 
body. On the other hand, P. ostreatus and A. bisporus did not show anti-inflammatory 
activity. However, P. ostreatus showed cytotoxicity in human tumor cell lines in 
opposition to A. bisporus, that didn't present cytotoxic activity. In conclusion, the results 
show that these mushrooms are a good source of compounds with antioxidant and 
cytotoxic capacity, with variations among species. 
 
Keywords: Nutraceutical formulations; Mycelium; Phenolic compounds; Ergosterol; 
Bioactivity. 
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RESUMO 
 
A importância de melhorar a qualidade de vida das pessoas tem despertado o interesse da 
indústria alimentar pelo desenvolvimento de novos produtos com características funcionais 
que possam estar associados a possíveis efeitos benéficos na saúde humana, quer a nível 
preventivo, quer terapêutico. Os alimentos funcionais e nutracêuticos apresentam na sua 
composição substâncias bioativas com efeitos benéficos e, portanto, tornam-se apelativos 
para muitos consumidores em todo o mundo. Os cogumelos são uma fonte de proteínas, 
vitaminas, minerais e, muitos outros compostos bioativos. Estes compostos, incluindo 
ergosterol, compostos fenólicos, tocoferóis, ácido ascórbico e carotenóides, têm sido 
associados a propriedades antioxidantes, anti-inflamatórias, antimicrobianas e citotóxicas, 
entre outras, relacionadas com os seus efeitos na promoção da saúde. Assim, o presente 
trabalho teve por objetivo desenvolver formulações nutracêuticas baseadas em micélio de 
Agaricus bisporus e Pleurotus ostreatus. O estudo destaca ainda o potencial da cultura in 
vitro como ferramenta para melhorar a produção de compostos bioativos em duas espécies 
de cogumelos diferentes. Por conseguinte, A. bisporus e P. ostreatus foram estudados 
quanto à sua composição em ácidos fenólicos e esteróis, atividade antioxidante (captação 
de radicais livres DPPH, poder redutor, inibição da descoloração do β-caroteno e inibição 
da formação de TBARS), efeito anti-inflamatório (inibição da produção de NO em células 
RAW264.7 estimuladas por LPS) e actividade citotóxica (usando Linhas celulares MCF-7, 
NCI-H460, HeLa, HepG2 e PLP2). Os micélios de A. bisporus e P. ostreatus foram 
cultivados em diferentes meios de cultura, sólidos e líquidos, e posteriormente submetidos 
a processos de extracção sólido-líquido; estas espécies analisadas apresentaram diferenças 
na taxa de crescimento e rendimento de biomassa. Em geral, o micélio de P. ostreatus 
apresentou teores mais elevados de compostos fenólicos e ergosterol (mas o micélio de A. 
bisporus produzido em PDA apresentou uma maior quantidade de ácido p-
hidroxibenzóico) e maior atividade antioxidante do que o corpo de frutificação 
correspondente. Por outro lado, A. bisporus e P. ostreatus não mostraram nenhuma 
atividade anti-inflamatória. No entanto, P. ostreatus mostrou citotoxicidade em linhas 
celulares tumorais humanas, ao contrário de A. bisporus que não apresentou atividade 
citotóxica. Em conclusão, os resultados mostram que estes cogumelos são uma boa fonte 
de compostos com capacidade antioxidante e citotóxica, com variações entre espécies. 
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Palavras-chave: Formulações nutracêuticas; Micélio; Compostos fenólicos; Ergosterol; 
Bioatividade. 
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CHAPTER 1. 
 
1. INTRODUTION 
 
In recent decades the demands of consumers in terms of food production have changed 
considerably. Consumers increasingly believe that food directly contribute to their health 
and well-being. Today's foods are not only intended to satisfy hunger and provide the 
necessary nutrients, but also to prevent disease and improve physical and mental well-
being of consumers. In this context, functional foods play a very important role. The 
growing demand for such foods can be explained by the rapid advances in science and 
technology, increasing health care costs, changes in effective food laws tam labels and 
product claims, the steady increase in life tenancy, the desire of older people to improving 
quality of life in their late years and the increased interest in maintaining good health 
through diet (Siro et al., 2008). 
The subject “nutraceuticals” and “functional foods” is experiencing a broad discussion in 
the scientific community, and with the recent improvements and biotechnological 
discoveries of recent decades, it becomes a recent research hot topic. 
According to DeFelice (1995) and subsequent references, “a nutraceutical is any substance 
that is a food or a part of food and provides medical or health benefits, including the 
prevention and treatment of disease” (DeFelice, 1995; Brower, 1998 and Rishi, 2006). 
Foods, known as “functional foods,” are thought to provide benefits beyond basic nutrition 
and may play a role in reducing or minimizing the risk of certain diseases and other health 
conditions (Cencic & Chingwaru, 2010). Nutraceuticals and functional characteristics of 
many traditional foods are being discovered and studied, while new food products are 
being developed to include beneficial components. By knowing which foods can provide 
specific health benefits, we can make food and beverage choices that allow us to take 
greater control of our health. 
Mushrooms belong to the kingdom Fungi, a group very distinct from plants, animals and 
bacteria. Fungi depend on other organisms for food, absorbing nutrients from the organic 
material in which they reside (Adamovic et al., 1998). 
Mushrooms have shown many biotechnological potential and have attracted the attention 
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of the pharmaceutical and food industries due to its nutritional value and the presence of 
numerous bioactive substances (Kalac, 2009). These molecules are responsible for the use 
of mushrooms as important partners in the complementary treatment of many diseases such 
as cancer, hepatitis, human papillomavirus (HPV) and human immunodeficiency virus 
(HIV). In addition to these therapeutic effects, mushrooms are also used in the prevention 
of diseases including cancer, diabetes, stroke, among others (Younis et al., 2014). 
According to Ferreira and collaborators (2010), in addition to the immunomodulating 
properties, mushrooms have effective substances for lowering cholesterol, which revert 
situations of hyperlipidemia, show antithrombotic activity reducing blood pressure, as also 
hypoglycaemic activity.  
The great majority of the studies reporting mushrooms’ properties are conducted with the 
fruiting bodies, but culture media used in mushroom’s cultivation have also been explored 
as potential sources of bioactive compounds (Ma et al., 2016). Otherwise, the in vitro 
culture of mycelia is becoming a promising alternative to obtain sources of bioactive 
compounds, mainly due to the shorter incubation time and easier culture conditions (less 
space needed, low probability of contamination and higher biomass yields when compared 
with fruiting bodies) (Gan et al, 2012 and Zhang et al., 2016). 
The fruiting bodies and mycelia of A. bisporus and P. ostreatus were previously studied 
for their chemical composition, antioxidant, anti-inflammatory and cytotoxic activities, 
after being harvested at different periods (Barros et al., 2009; Reis et al., 2012; Barreira et 
al., 2014; Morro et al., 2012; Ferreira et al., 2010; Martins et al., 2012; Taofiq et al., 2015; 
Younis et al., 2014; Silva, 2015).  However, the present study goes further and compares 
fruiting bodies, mycelia and culture media in terms of bioactive properties and compounds. 
Thereby, the main objective was to develop nutraceutical formulations based on fruiting 
body and mycelium of A. bisporus and P. ostreatus, as also the corresponding culture 
media, highlighting the potential of in vitro culture as a tool to improve production of 
bioactive compounds by two different mushroom species. 
 
 1.1. Description of the species to be studied 
Mushrooms (Figure 1) are macrofungi with distinctive and visible fruiting bodies 
belonging to the phylum Basidiomycota and Ascomycota. Today, mushrooms are greatly 
appreciated and marketed throughout the world because of its characteristic taste and 
culinary value, as well as their nutritional properties (Ferreira et al., 2009 and Ferreira et 
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al., 2010). 
 
Figure 1: Schematic representation of mushrooms (Kalac, 2000). 
 
Agaricus bisporus L., known as champignon, white mushroom or white button mushroom, 
belongs to the phylum Basidiomycota. This species has several demonstrated and valuable 
medicinal properties including anti-tumor, anti-aromatase, antimicrobial, 
immunomodulatory, anti-inflammatory and antioxidant (Stojkovic et al., 2014). 
Pleurotus ostreatus (Jacq. Ex Fr.) P. Kumm., better known as oyster mushroom or 
‘‘repolgas’’, also belongs to the phylum Basidiomycota. It is the edible mushroom most 
produced all over the world. The production and consumption of Pleurotus is increasing, 
not only for its easily, quickly growing and organoleptic characteristics, but also for its 
nutritional value and medicinal properties (Ramos et al., 2011). Its medicinal properties 
include immunologic, antitumor, anti-inflammatory and antimicrobial activities, among 
others (Fernandes et al., 2015). 
1.1.1. Agaricus bisporus L. 
The consumption of mushrooms is an ancient practice and literature reports its existence 
since the beginning of civilization. The mushroom Agaricus bisporus (Figure 2) is the 
most important fungi among the edible mushrooms cultivated worldwide (Sanchez et al., 
2008). With the advancement of technology, today much of the research is directed to the 
genetic improvement of strains of A. bisporus, because these are genetically unstable (Li et 
al., 1994 and Umar & Van Griensven, 1999). 
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Figure 2: Agaricus bisporus. 
 
The mushrooms are gaining worldwide recognition as important functional foods and as 
sources of therapeutical molecules for the treatment of some diseases (Chang, 2008). In 
addition to these qualities edible mushrooms are very versatile in cooking, as they can be 
baked, boiled, grilled or sautéed, and even combined with soups, patés, salads and teas 
(Brill, 2002). 
Beelman and collaborators (2003) published a study related with bioactive compounds in 
A. bisporus, and reported for this species a higer nutritional value but similar bioactive 
components in comparison with Lentinus edodes and Pleurotus spp. 
A. bisporus has a cap of 5 to 12 cm, convex with curved edge, becoming plane with age, 
white color, smell and mild taste; it has a pink-brown laminae becoming purple-brown and 
finally dark brown, a stem of 2 to 5 cm with bulbous base, and dark brown spores 
(Breitenbach & Kranzlin, 1995 and Sanchez, 2008). 
A. bisporus is one of the edible cultivated fungi with higher economic importance. It is a 
microscopic fungus, with distinctive fruiting body, being large enough to be seen with the 
"naked eye" and be picked up by hand. It has no cholesterol, and insignificant levels of 
vitamin A or vitamin C, but it is a source of some B vitamins, in particular, riboflavin (B2), 
niacin (B3) and pantothenic acid (B5), ergosterol, representing 90% of its sterol fraction 
(when exposed to ultraviolet light is converted to pro-vitamin D), essential minerals 
(especially selenium, copper and potassium), phenolic compounds, having also a high 
amount of crude protein (Barros et al., 2008; Chang, 2008 and Barreira et al., 2014). 
A. bisporus (white and brown) exhibit total phenolic contents of 23.34 and 37.33 mg GAE 
(gallic acid equivalents)/g of extract, respectively (Reis et al. 2012b), and a concentration 
of free ergosterol (analysed by HPLC-UV) of 7.80 mg/g dry matter (Jasinghe, 2005). The 
taxonomic classification is in the following table (Table 1). 
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Table 1: Taxonomic classification of Agaricus bisporus (Braga et al., 1998). 
Kingdom: Fungi 
Division: Basidiomycota  
Class: Homobasidiomycetes  
Order: Agaricales  
Family: Agaricaceae  
Genus: Agaricus 
Species  A. bisporus 
 
1.1.2. Pleurotus ostreatus (Jacq. Ex Fr.) P. Kumm. 
Among the many existing edible mushrooms, only a few species are used as food and 
commercially cultivated. The three most cultivated species are Agaricus brasiliensis, 
Lentinula edodes and Pleurotus ostreatus (Figure 3) (Ribas, 2006), being the genus 
Pleurotus the third type most produced worldwide (Dias, 2010). 
 
 
 
 
 
 
Figure 3: Pleurotus ostreatus. 
P. ostreatus presents a convex cap plan-convex, grayish or whitish color and with a 
diameter from 5 to 15 cm. At the bottom of the hat, the blades are arranged radially, with 
whitish and rather narrow. This species also has a side foot hair and very short compared to 
the diameter of the cap. The edible part has a whitish color with pleasant and intense 
fragrance (Coelho, 2012). 
Mushrooms of the Pleurotus genus represent a low cost food with high protein content, 
essential amino acids, higher percentage of unsaturated fatty acids in comparison with 
saturated fatty acids, various vitamins and minerals, and low levels of nucleic acids, sugars 
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and calories (Manzi et al., 2001 and Bonatti et al., 2004). Moreover, the advances made in 
the field of biotechnology allowed the identification of important medicinal properties of 
mushrooms attributed to various bioactive molecules, such as polysaccharides, ergosterol, 
phenolic compounds, lecithins and some immunomodulatory amino acids including 
arginine and glutamine (Viegas et al., 2006). 
The total phenolic content in P. ostreatus is 12.45 mg GAE/g of extract (Reis et al., 2012b) 
and its concentration in free ergosterol (determined by HPLC- UV) is 4.40 mg/g dry matter 
(Jasinghe, 2005). 
P. ostreatus is a decomposer mushroom of vegetable matter. This species and other species 
of mushrooms produce extracellular ligninolytic enzymes such as lignin peroxidase, 
manganese peroxidase and laccase, which are involved in lignin degradation. This feature 
gives mushrooms the ability to grow on the trunks of living or dead trees (Martinez et al., 
2001 and Coelho, 2012). The taxonomic classification of P. ostreatus species is presented 
in the following table (Table 2). 
 
Table 2: Taxonomic classification of Pleurotus ostreatus (Adapted of Alexopoulos et al., 1996). 
  Kingdom: Fungi 
Division: Basidiomycota 
Class: Agaricomycetes 
Order: Agaricales 
Family: Pleurotaceae 
Genus: Pleurotus 
Species P. ostreatus 
  
1.2. The mushrooms as a source of bioactive compounds 
The mushrooms are consumed by people of diverse cultures, both for its gastronomic 
characteristics, as also medicinal features. However, its use as functional foods is more 
evident in Eastern cultures, in which the use of mushrooms in health maintenance began 
thousands of years ago with the Chinese (Chang, 1996). 
The mushrooms have a lot of bioactive compounds. Examples of these compounds in 
mushrooms are tocopherols, phenolic compounds (phenolic acids) (Table 3), ergosterol 
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(Table 4), among others, some of them responsible for their nutraceutical potential (Barros 
et al., 2008a; Barros et al., 2009 and Ferreira et al., 2009). Nutraceuticals present in 
mushrooms have been related to their antioxidant, anti-inflammatory and cytotoxic 
activities (Fernandes et al., 2015). 
Table 3: Phenolic acids in mushrooms reported in the literature (A - Barros et al., 2009; B - Muszyńska et 
al., 2013; C - Reis et al., 2012). 
Phenolic acids acid (g/g dw) 
Species Sample 
Gallicaci
d  
Protocatechui
c acid  
p-
Hydroxybenzoic 
acid 
p-Coumaric     
acid  
Cinnamic    
acid  
Agaricus 
bisporus 
Mushro
om 
63 ± 13
C
 Nd nd 2.31 ± 0.06
 C
 0.38 ± 0.02
 C
 
Nd Nd 26 ± 2
A
 nd 8.7 ± 0.7
A
 
Myceliu
m 
31 ± 4
C
 Nd 0.02 ± 0.001
 C
 3.7 ± 0.2
 C
 0.76 ± 0.03
 C
 
Pleurotus 
ostreatus 
Mushro
om 
Nd 0.77 ± 0.02
C
 1.56 ± 0.06
C
 0.81 ± 0.03
C
 0.23 ± 0.02
C
 
Nd 2.52 ±0.03
B 
3.60 ±0.05
B
 nd 1.09 ±0.01
B
 
Myceliu
m 
Nd Nd 0.05 ± 0.0001 
C
 nd 9.7 ± 0.9
 C
 
dw- dry weight; n.d. – not detected. 
 
Table 4: Ergosterol content in mushroom fruting bodies reported in the literature (A -
 
Barreira et al., 2014 
and B- Villares et al., 2014). 
Species Ergosterol (mg/100 g dw) 
Agaricus bisporus 
352±1 A 
6.4±0.2 B 
Pleurotus ostreatus 
104±1
 
A 
3.3 ± 0.2 B 
 
1.2.1. Phenolic acids 
Phenolic compounds range from simple molecules up to other with high degree of 
polymerization (Bravo, 1998 cited by Smith et al., 2002). The presence of these 
compounds has been highly documented due to its pharmacological and antinutritional 
activities (Nagem et al., 1992; Gamache et al., 1993; Ivanova et al., 1997; Aziz et al., 
1998; Fernandez et al., 1998 and Hollman Katan, 1998 cited by Soares, 2002). 
The phenolic compounds usually appear as glucosides and esters rather than the free 
compounds, because of the higher stability of these molecules (Fraga, 2010). According to 
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Ferreira and collaborators (2009), phenolic compounds are described as biologically active 
substances having antioxidant, anti-inflammatory or anti-tumor properties. Phenolic 
molecules are hydroxylated aromatic compounds having in their basic constitution one or 
more aromatic rings with one or more hydroxyl groups. They include a large number of 
subclasses, such as phenolic acids, flavonoids, tannins, stilbenes, among others, which 
indicate a large diversity of chemical structures. The flavonoids are the most widely 
distributed sub-class. They are found in higher levels in plants and vegetables but 
mushrooms also have significant amounts of phenolic compounds (Ferreira et al, 2009 and 
Palacios et al, 2011). 
The major phenolic compounds from mushrooms are phenolic acids. Phenolic acids are 
characterized by having a benzene ring, a carboxyl group and one or more hydroxyl and/or 
methoxyl groups in the molecule, imparting antioxidant properties both to food as to the 
organism after ingestion (Crozier et al., 2006 and Fraga, 2010 cited by Carocho & Ferreira, 
2013). Phenolic acids are usually found in vegetables and fruits present in our diet, and 
some of which are among the most bioactive and therapeutically useful substances (Apak 
et al., 2007 cited by Ferreira et al., 2009). According to Soares (2002), phenolic acids, in 
addition to its presence in their natural form, can also bind to each other or other 
compounds. 
Phenolic acids can be divided into two main groups, hydroxybenzoic acids (Table 5) and 
hydroxycinnamic acids (Table 6), which are derivatives of the non-phenolic benzoic and 
cinnamic acids, respectively. The hydroxybenzoic acid derivatives generally occur in 
bound form, and are typically components of complex structures such as tannins and 
hydrolyzable lignins. It can also be found bound to sugars or organic acids in foods, 
exhibiting seven carbon atoms and being simple phenolic acids found in nature. The 
derivatives of hydroxycinnamic acid are mainly present in the bound form as structural 
components of the cell wall, such as cellulose, lignin and proteins, as well as associated 
with organic acids such as tartaric acid or quinic acid, by ester bonds and exhibit nine 
carbon atoms, being the structures with seven carbons the most commonly found in the 
vegetable and fungi kingdoms (Ferreira et al., 2009).  
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Table 5: Chemical structure of the benzoic acid derivatives found in mushrooms (Ferreira et al., 2009). 
* Aldeydes are groups under the corresponding phenolic acid class. 
Benzoic acid 
derivatives 
Substitution  
X  
R
1  R
2  R
3  R
4  
p-Hydroxibenzoic  
 
COOH  H  H  H  OH    
 
 
 
 
 
 
 
 
 
 
Protocatechuic  
 
COOH  H  H  OH  OH  
Gallic  
 
COOH  H  OH  OH  OH  
Gentisic  
 
COOH  OH  H  H  OH  
Homogentisic  
 
CH2COOH  OH  H  H  OH  
Vanillic  
 
COOH  H  OCH3  OH  H  
5-Sulphosalicylic  
 
COOH  OH  H  H  HSO3  
Syringic  
 
COOH  H  OCH3  OH  OCH3  
Veratric  
 
COOH  H  OCH3  OCH3  H  
Vanillin  
 
CHO*  H  OCH3  OH  H  
 
Table 6: Chemical structure of the cinnamic acid derivatives found in mushrooms (Ferreira  et al., 2009). 
* The carboxylic group is esterified with quinic acid. 
Cinnamic acid 
derivatives  
 
Substitution 
 
 
X  R
1  R
2  R
3  R
4  
p-Coumaric  
 
H  H  H  OH  H     
o-Coumaric  
 
H  OH  H  H  H  
Caffeic  
 
H  H  OH  OH  H  
Ferulic  
 
H  H  CH3 O  OH  H  
Sinapic  
 
CH3O  H  CH3O  OH  CH3O  
3-O- caffeoylquinic  
 
*  H  OH  OH  H  
4-O- caffeoylquinic *  H  OH  OH  H  
5-O- caffeoylquinic *  H  OH  OH  H  
 
1.2.2. Ergosterol 
Sterols are special forms of steroids that can be found in animals (zoosterols), plants 
(phytosterols) and fungi (mycosterols) (Barreira & Ferreira, 2015). They consist of a 
tetracyclic structure of four rings linked together, consisting of three to six carbon atoms 
and other ring with five carbon atoms (steroid nucleus) (Figure 4) with a hydroxyl group 
on the C3 position and an aliphatic chain linked to the steroid nucleus (Fahy et al., 2005 
cited by Diz, 2015). 
Ergosterol is the main sterol present in mycelial cells or membranes of most fungi. The 
highest levels of this compound are in phospholipid layer of the membrane where fungal 
ergosterol plays an important structural and hormonal function in cell cycle progression 
(Ricardo, 2015). 
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Figure 4: Steroid nucleus (Barreira & Ferreira, 2015). 
 
The ergosterol is abundant in edible mushrooms (Kuo et al., 2011). According Jasinghe 
and Perera (2005), the nature of ergosterol varies depending on the mushroom species, 
within the same species, with different varieties of mushrooms and with the maturity stage. 
These authors indicate that the concentration of sterols in mushrooms, especially 
ergosterol, depends on the part of the mushroom tissue used, maturity stage and growth 
conditions. Savón and collaborators (2002) cited by Diz (2015) also reported that, in 
relation to specific genetic traits, ergosterol content in mushrooms also depends on 
environmental factors such as light, heat, temperature, humidity and the type of substrate 
used on the growth of mushrooms. 
The ergosterol is present in two basic forms, namely, as free ergosterol and esterified 
ergosterol. The relative abundances of free and esterified ergosterol are different according 
with the species. The free ergosterol is most important for the integrity of the cell and 
contributes to various cellular functions. The ergosterol ester, kept in cytosolic lipid 
particles, is a fixed storage form of sterol and can serve as an intermediate for the 
ergosterol functioning (Barreira & Ferreira, 2015). 
According to Diz (2015), ergosterol is a molecule with high commercial value and is the 
main sterol in fungi. For example, it is the most abundant mycosterol in Agaricus bisporus, 
and is also found in corn oils, cottonseed, groundnut and linseed (Lagarda et al., 2006 cited 
by Barreira & Ferreira, 2015). Zymosterol, ergosta- 5,7-dienol, 24-methyl cholesterol, and 
methylene cholesterol are also important examples of sterols in fungi (Mattila et al., 2002 
and Christie, 2013 cited by Barreira & Ferreira, 2015). 
The ergosterol or provitamin D2, whose chemical name is 5,7,22-ergostatrien-3β-ol has the 
empirical formula C28H44O and the relative molecular mass of 396.36 g/mol. The 
ergosterol compound is solid, crystalline and colorless, and has a melting point in the range 
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of 161-166 ºC. In vacuum, it supports the temperature of 250 ºC without decomposition 
(Barreira et al., 2014 and Ferreira, 1985 cited by Ricardo, 2015).  
A metabolite, which is commonly found in mushrooms, is ergosterol peroxide, having 
become a very promising compound for health and significant pharmacological activities, 
such as antioxidant, antimicrobial and antitumor. In addition, these compounds reduce the 
incidence of cardiovascular disease and pain associated with inflammation by inhibiting 
the cyclooxygenase enzyme (Yuan et al., 2007). 
The antitumor activity of ergosterol may be due to its inhibitory capacity of angiogenesis 
(development of new blood vessels from existing ones) induced by solid tumors (Takaku et 
al., 2001; Zaidman et al., 2005; Slominski et al., 2005 cited by Ricardo, 2015). 
Other studies have indicated that free ergosterol (the main component of the lipid portion) 
was responsible for the antioxidant activity of the hexane extract of Agaricus bisporus 
brown mushroom (positive correlation between ergosterol content and antioxidant activity; 
r2 > 0.89) (Shao et al., 2010). Furthermore, ergosterol may exhibit hypocholesterolemic 
properties, since it is able to reduce cholesterol levels in the serum (Gil-Ramirez et al., 
2013).   
 
1.3. Bioactivity of extracts rich in phenolic acids and ergosterol 
Edible mushrooms grow in darkness and dampness in highly competitive environments 
and protect themselves from microbes by excretion of natural substances; this explains 
their richness in bioactive compounds. They are appreciated throughout the world not only 
for its organoleptic characteristics but also for its nutritional and functional properties 
(Ferreira et al., 2010). 
The presence of bioactive compounds, namely ergosterol and phenolic compounds, could 
explain their antioxidant, anti-inflammatory, cytotoxic and antimicrobial properties 
(Ricardo, 2013). 
1.3.1. Antioxidant activity 
In general, the term antioxidant is used for sorting molecules which are present in low 
quantities in the substrate that is oxidizable and which reacts rapidly in order to suppress or 
prevent oxidation (Magalhães, 2009). 
Maintaining the balance between the production of free radicals and antioxidant defenses 
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(enzymes and non-enzymatic molecules) is a prerequisite for the normal functioning of the 
body. When this equilibrium tends to uncontrolled production of free radicals means that 
the body is in oxidative stress and in such situations, excess free radicals can oxidize and 
damage cell lipids, proteins, DNA (deoxyribonucleic acid) and RNA (ribonucleic acid), 
inhibiting their normal function, leading to various diseases such as atherosclerosis, 
diabetes, cirrhosis, cataracts, premature aging and cancer (Valko et al., 2007 and Ferreira 
et al., 2009). 
According Ferreira and Abreu (2007), the exposure of organisms to free radicals, led to the 
development of endogenous defense mechanisms to eliminate them. But despite all 
organisms possess defense and repair systems that have evolved to protect them against 
oxidative damage, these systems are often insufficient to prevent completely, the damage 
induced by oxidative stress (Yang et al., 2001). Nevertheless, the presence of antioxidants 
in the diet can help the endogenous defense system, reducing oxidative damage (Fang et 
al., 2002; Liu, 2003 and Barros et al., 2008b). 
Currently, antioxidants have a range of applications, from food to pharmaceutical industry, 
as also plastic’s industry and lubricating oils. The best known synthetic antioxidants are 
BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), TBHQ (tert-
butylhydroquinone) and PG (propyl gallate), which are widely used in both food and 
pharmaceutical industry. However, BHA and BHT have been restricted in their use due to 
possible toxic and carcinogenic effects (Silva, 2015). Thus, the use of antioxidants from 
natural sources such as mushrooms, assumes increasing importance. 
This antioxidant activity in mushrooms is related mainly to its high content of phenolic 
compounds, are recognized as excellent antioxidants because of their ability to block free 
radical by transfer of a single electron and excellent redox properties of the phenolic 
hydroxyl groups (Cheung, 2008; Kim et al, 2008; Jayakumar et al, 2009 cited by Ricardo 
2013). 
Recent studies indicate a direct relationship between the content of phenolic compounds 
and antioxidant activity of several species of mushrooms. A study performed with 
methanol extracts of some cultivated species of edible mushrooms from Portuguese origin, 
such as Agaricus bisporus (white), Agaricus bisporus (brown), Pleurotus ostreatus, 
Pleurotus eryngii and Lentinula edodes revealed that these species have a scavenging 
effect on DPPH• (2,2-diphenyl-1-picrylhydrazyl) radicals, inhibit lipid peroxidation and 
have a strong reducing power (Table 7). (Reis et al., 2012b). 
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Agaricus bisporus and Pleurotus ostreatus, as well as other species of cultivated edible 
mushrooms are a good source of natural antioxidants, presenting in its constitution 
phenolic compounds, especially phenolic acids, followed by tocopherols (mainly α-
tocopherol), ascorbic acid and carotenoids, especially the β-carotene (Barros et al., 2009 
and Ferreira et al., 2009). According to Rodriguez-Vaquero and collaborators (2007) and 
Karaman and collaborators (2010), the strongest antioxidant properties and capability of 
cell protection against hydrogen peroxide was evident for vanillic acid, and among 
cinnamic acid derivatives, for caffeic acid. p-Hydroxybenzoic, gallic and protocatechuic 
acids found in mushrooms are characterized by antioxidant, antibacterial, antiviral, 
antifungal, anti-inflammatory and gastric secretion-stimulatory actions, documented by in 
vitro and in vivo studies. However, according to Heleno and collaborators (2015) little is 
known about the bioactive phenolic forms in vivo. 
Studies have shown that ergosterol and its peroxidation products may also contribute to 
potential health benefits and significant pharmacological activities, namely antioxidant 
activity (Yuan et al., 2007). 
Table 7: Reducing power, scavenging activity and lipid peroxidation inhibition of the studied edible 
mushrooms according with Reis et al. (2012b). 
Species Sample 
 
Reducing power 
 
Scavenging Lipid peroxidation inhibition 
Ferricyanide/Pru
ssian blue assay 
(EC50; mg/mL) 
DPPH scavenging 
activity assay 
(EC50; mg/mL) 
β-carotene/ 
linoleate assay 
(EC50; mg/mL) 
TBARS assay 
(EC50; 
mg/mL) 
 Agaricus 
bisporus 
Mushroom 
1.80 ± 0.03 3.13 ± 0.09 3.4 ± 0.1 
2.9 ± 0.5 
3.63 ± 0.02
F 
9.61 ± 0.07
F 
21.4 ± 0.5
F 
Mycellium 8.12 ± 0.06 40 ± 2 2.4 ± 0.6 0.87 ± 0.76 
Pleurotus 
ostreatus 
Mushroom 3.31 ± 0.03 
6.5 ± 0.2 2.7 ± 0.2 
2.6 ± 0.9 
5.1 ± 0.7
G 
440 ± 43
G 
Mycellium 4.7 ± 0.2 
58 ± 3 17 ± 2 
1.0 ± 0.3 
29 ± 6
G 
392 ± 51
G 
Concerning Folin-Ciocalteu assay, higher values mean higher reducing pawer: for the other assays, the 
results are presented in EC50 values, what means that higher values correspond to lower reducing power or 
antioxidant potential. EC50: Extract concentration corresponding to 50% of antioxidant activity or 0.5 of 
absorbance for the Ferricyanide/Prussian blue assay. 
F- 
Martins et al., 2012. 
G- 
 Silva, 2015. 
1.3.2. Anti-inflammatory activity 
Inflammation is considered part of the complex biological response to eliminate pathogens, 
damaged cells, or irritation. This response leads to many physical symptoms, such as fever, 
pain, swelling, etc. When cells are exposed to immune stimulants, pro-inflammatory cells 
such as macrophages, or other host cells start to produce cytokines and other mediators that 
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initiate the process of inflammation (Taofiq et al., 2015). 
Among the various inflammatory mediators, the most common are the interleukins (IL-1β, 
IL-6, IL-8), tumor necrosis factor (TNF-α ), nuclear-kB factor (NF-kB), intercellular 
adhesion molecule 1 (ICAM-1) inducible type of cyclooxygenase-2 (COX-2), 
prostaglandin E2 (PGE2), 5-lipoxygenase (5-LOX), and the inducible nitric oxide synthase 
(iNOS), which leads to the production of reactive nitrogen species such as nitric oxide 
(NO). Over-production of these inflammatory mediators leads to different types of cellular 
damage (Kanwar et al., 2009 cited by Taofiq et al., 2015). 
Nowadays, NSAIDs are generally administered to reduce inflammation in the body. But 
long-term administration of NSAIDs has significant side effects on the gastrointestinal 
tract (Smalley et al., 1995 and Sinha et al., 2013), as well as other serious complications 
such as hypertension and cardiovascular toxicity, etc. (Dugowson & Gnanashanmugam, 
2006 and Meek et al., 2010). 
Many bioactive compounds present in mushrooms exhibit significant anti-inflammatory 
properties (Table 8), based on their ability to reduce the production of inflammatory 
mediators (Ferreira et al., 2009; Elsayed et al., 2014 and Heleno et al., 2015). Several 
compounds have been identified as potential natural and safe drugs, without the harmful 
side effects characteristic of NSAIDs. These compounds are responsible for anti-
inflammatory activity, and include mostly beta-glucans, triterpenoids, glycoproteins and 
phenolic compounds (Taofiq et al., 2015). 
According to Yuan and collaborators (2007) the products of ergosterol peroxidation reduce 
pain associated with inflammation by inhibiting the enzyme cyclooxygenase. 
As previously demonstrated, the edible white button mushroom (Agaricus bisporus) 
enhanced NK cell activity in mice through the increased production of IFN-δ which 
induced maturation of dendritic cells, and TNF-α, increasing the production of IL-12 (Wu 
et al., 2007 and Ren et al., 2008). 
Oyster mushrooms (Pleurotus species) belong to the world of consumed mushrooms that, 
in addition to their nutritional value, demonstrate health-promoting (antioxidant, anti-
atherosclerotic, anticancer and immunomodulatory) effects (Jayakumar et al., 2008). 
Glycosphingolipid when isolated from Pleurotus ostreatus, inhibited leukocyte migration 
to acetic acid-injured tissues (Smiderle et al., 2008). 
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Table 8: Some previous studies on anti-inflammatory activity of the two studied mushroom species. 
Species Inhibition of NO production References 
Agaricus bisporus 30% at 0.5 mg/mL 
Moro et al., (2012) 
Pleurotus ostreatus 15% at 0.5 mg/mL 
Extract concentrations responsible for 50% of reduction of NO production (EC50 values) in RAW 
264.7 cell line 
Species EC50 values (μg/mL) References 
Agaricus bisporus 190 ± 6 
Taofiq et al., (2015) 
Pleurotus ostreatus 96 ± 1 
 
1.3.3. Cytotoxic activity 
Cancer is a disease characterized by a cell population, which grow and divide without 
respect to normal limits, invade and destroy adjacent tissues. But, the cells have enzyme 
systems capable of repairing the majority of such damages. Although these systems are 
efficient, some injury or even spontaneous errors during DNA replication are not repaired 
(Kellof & Sigman 2000).  
The causes of cancer are diverse, complex, and only partially understood. Cancers are 
primarily an environmental diseases with 90–95% of cases attributed to environmental 
factors and 5–10% due to genetics common environmental factors that contribute to cancer 
death including tobacco (25–30%), diet and obesity (30–35%), infections (15–20%), 
radiation (both ionizing and non-ionizing, up to 10%), stress, lack of physical activity, and 
environmental pollutants. Cancer causing viral infections such as HBV/HCV and HPV are 
responsible for up to 20% of cancer deaths in low and middle-income countries (Younis et 
al., 2014). 
There are different possibilities to cancer treatment including surgery, chemotherapy, 
radiation therapy, and palliative care. These treatments are used depending on the type, 
location and grade of the cancer as well as the person's health and wishes. Treatment 
options are often expensive and have side effects. For example, most chemotherapeutic 
agents for the treatment of cancer destroy tumors and arrest cancer progress but also 
damage healthy cells and tissues This situation has forced scientists to search for new 
antitumor substances from various natural sources to develop more effective and safer 
agents to inhibit the growth of cancer cells, and not causing harm to the host (Ajith & 
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Janardhanan, 2003). 
Popovic and collaborators (2013) defines mycotherapy as the study of the use of extracts 
and compounds derived from mushrooms as medicines or health promoting agents. 
Mycotherapy of cancer is a scientific field relatively new and promising, which deals with 
anticancer agents derived from mushrooms.   
Identification of active ingredients in the extracts, in other words, the isolation of new anti-
tumor mushroom substances has become a matter of great importance, in view of the 
complexity and distribution of various types of cancer in the world population (Zong et al., 
2012). 
A wide variety of compounds and complex fractions have been isolated and/or purified 
from some edible mushrooms, with particular importance in relation to anticancer and 
cancer preventive activity (Table 9). These activities are attributed mainly to 
polysaccharides, sterols, phenolic compounds etc. (Takaku et al., 2001; Liang et al., 2011; 
Vaz et al., 2012 and Zong et al., 2012). 
Some species of the genera Pleurotus, Agaricus, Flammulina, Ganoderma, among others 
are medicinally valuable due to its anti-tumor activity (Table 9) (Ferreira et al., 2009 and 
Gunawardena et al., 2013 cited by Younis et al., 2014). 
According to Song and collaborators (2009), Ma and collaborators (2013) (cited by 
Popovic et al., 2013), various derivatives of ergosterol have been isolated from 
mushrooms, for example, ergosterol peroxide and trametenolic acid, and showed 
cytotoxicity in prostate cell lines and human breast carcinoma. 
According to Takaku and collaborators (2001), oral administration of ergosterol (400 and 
800 mg/kg for 20 days) to mice with Sarcoma 180, reduced significantly the tumor growth 
without any side effects. Other studies showed that ergosterol peroxide induced death of 
miR-378 transfected cells (Wu et al., 2012), and ergosterol peroxide and trametenolic acid 
isolated from Inonotus obliquus exerted cytotoxic activity in prostate cell lines and human 
breast carcinoma (Ma et al., 2013). 
Phenolic compounds isolated from mushrooms also showed high cytotoxic activity against 
human tumor lines cells. Protocatechuic acid (phenolic acid) and a related compound 
(cinnamic acid), induced significant inhibition of cell growth of a human non-small lung 
carcinoma cell line (NCI H460); the effect of cinnamic acid was the most pronounced (Vaz 
et al. 2012). 
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Table 9: Compounds with antitumor potential found in the studied mushroom species (Ferreira et al., 2010) 
and cytotoxic activity of extracts obtained from the same speices against the two carcinoma cell lines 
(Younis et al., 2014). 
Mushroom 
Species 
Antitumor Agents References 
Agaricus 
bisporus 
490 Quinone (-L-glutaminyl-4-hydroxy-2,5-benzoquinone) Zaidman et al. (2005) 
Selenium Tiffany et al. (1978) 
Lectins Wang et al. (1998) 
Pleurotus 
ostreatus 
Selenium Zaidman et al. (2005) 
Pleuran Bobek & Galbavy (2001) 
Mushroom 
Species 
Sample 
HepG2 HeLa 
Maximum 
inhibitory % 
IC50 (μg/mL) 
Maximum 
inhibitory % 
IC50 (μg/mL) 
Agaricus 
bisporus 
Fruiting bodies 66.6±3.2 30.2±2.2 71.3±1.9 28.8±1.8 
Mycelia 41.1±2.1 54.9±2.4 57.4±2.9 38.7±1.9 
Pleurotus 
ostreatus 
Fruiting bodies 70.4±2.8 30.4±1.9 70.9±2.7 26.5±1.8 
Mycelia 40.8±2.6 56.3±2.5 45.2±1.5 52.2±2.5 
IC50: Extract concentration corresponding to 50% of cytotoxic activity. 
 
1.4. In vitro culture as a tool to improve the production of bioactive 
compounds 
The in vitro culture aims to clarify the optimum conditions for fungal growth, regarding 
culture medium, temperature and time of incubation and this knowledge is a prerequisite 
for commercial cultivation in formulated substrate (Hatvani, 2001). In vitro culture 
emerges as a biotechnological tool feasible for the production of bioactive compounds that 
can be used in several areas, and particularly in order to make additional efforts for the 
sustainable conservation and rational use of biodiversity (Karuppusamy, 2009 cited by 
Dias et al., 2016). 
1.4.1. Advantages and disadvantages of in vitro culture 
According to Peter and collaborators (2005) and Kolene and collaborators (2008) (cited by 
Dias et al., 2016) the World Health Organization (WHO) estimates that 80% of the 
population still depends today on traditional medicine for primary health care. 
Furthermore, many of the anticancer and anti-infeccious drugs available on the market are 
derived from natural products. Within the requirement of uninterrupted market naturally 
derived products faces an environmental concern regarding the loss of natural populations, 
genetic diversity, habitat degradation and even species extinction (Roberto & Francesca, 
2011). 
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In 1994, the United Nations Food and Agriculture Organization (FAO) has authorized the 
use of in vitro culture techniques as a method for the production of food natural 
compounds (Anand, 2010 and Roberto & Francesca, 2011). In 2002, FAO published a 
report in association with the IAEA (International Atomic Energy Agency - Division of 
Nuclear Techniques in Food and Agriculture) referring to the theme of in vitro culture 
techniques for the production of bioactive compounds as having a high value, indicating 
how it can be carried out more economically by researchers and industry (FAO/IAEA, 
2002). 
The cells of species grown in vitro synthesize, accumulate and sometimes exude many 
classes of metabolites. The bioactive compounds are of particular interest, and much effort 
has been devoted to getting some of the most precious and therapeutic properties (Vanisree 
& Tsay, 2004). 
Murthy and collaborators (2015) developed a safety assessment of food ingredients 
obtained by in vitro culture and proposed some protocols for evaluating the toxicity of 
these compounds and also its potential bioactivity. The in vitro culture includes handling 
under aseptic conditions and in case of plant culture, it must be carried out in a medium 
under controlled conditions of light, humidity and temperature (Smetanka 2008 cited by 
Dias et al., 2016). This controlled production system allows increased uniformity and 
standardization of extracts, such as the concentration of the desired compounds, 
maintaining the same genetic characteristics of the best clones for production (Chaturvedi 
et al., 2007 Cited by Dias et al., 2016). 
The combination of the engineering process, biotechnology and biochemistry led to a 
significant improvement in production yields, especially for the in vitro culture as the 
preferred method for the production of bioactive compounds (Zhou & Wu, 2006 and 
Kolewe et al., 2008 cited by Dias et al., 2016). 
Many advantages are associated with the in vitro production of bioactive compounds, for 
example: control and optimization of production conditions; low probability of 
contamination; preservation of the microorganism for additional studies (Black, 1997); 
control of the final product; selection of the best clones by genetic engineering; producing 
pure compounds; improving the nutritional effect of the produced species; reduction of 
undesired compounds; free production of herbicides and pesticides; chemical synthesis of 
the novel compounds; production is not dependent on climatic and geographical conditions 
(Verpoorte et al., 1999 and Chattopadhyay et al., 2002 cited by Dias et al., 2016). 
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However, according to Anand (2010), the most important advantage of in vitro culture is 
its ability to provide continuous, sustainable, economic and viable production of natural 
compounds, regardless of the geoclimatic conditions and a highly controlled environment. 
The in vitro culture, as any other process is sensitive to some problems of environmental or 
biological order, which affect directly the development of the cultures. Among these 
problems can be mentioned: low rate of development; it may happen a partial or complete 
loss of culture. Moreover, if the production on a large scale requires costly equipment, the 
procedure requires special care and careful observation; there may be error in the identity 
of the organisms after the culture; risk of infection, if precautions are not taken; risks of 
genetic variation (Engelmann, 1991; Santos et al., 2001 and Ahmed et al., 2008). 
 
1.4.2. Mycelium production  
The mycelium is the mass of hyphae that makes up the vegetative body of a mushroom. 
Colonies of mushrooms comprised of mycelium are found on the ground and in many 
other substrates. A single spore germinates in a monokaryotic mycelium, which cannot 
sexually reproduce; when two compatible monokaryotic mycelia join and form a 
dikaryotic mycelium, this mycelium can form fruiting bodies such as mushrooms (Leiva et 
al., 2015). 
The mycelial growth for a period of time has several stages with typical physiological 
properties (Montini et al., 2006). The extent of this growth can be done in different ways, 
namely radial growth, vigor, growth rate and weight of the mycelium. Under experimental 
conditions, the use of solid culture medium for evaluation of fungal growth is considered 
appropriate because, in nature, the fungi are developed commonly on solid substrates, such 
as plant debris, animals or the soil (Bononi et al., 1999). Savoie and collaborators (1995) 
recommended the use of a composition of culture medium similar to growth substrate. 
The inoculum is obtained by growing the cultivated mushroom's mycelium in Petri dishes 
or flasks. In order to inoculate the mycelium, the inoculum must be created in an artificial 
culture medium in a lab. Cultures on agar and in liquid media (entirely artificial systems) 
are excellent models and are indispensable for mycelium development. It must be pointed 
out that the medium used to grow the mycelium is often specific to a certain mushroom 
species. Mycelium growth is strongly influenced by the in vitro conditions, such as the 
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period of incubation, temperature, pH, size of the inoculum, etc. (Leiva et al., 2015). 
The mycelia mushrooms are usually isolated from sporocarps on solid or liquid media  
(Melin-Norkrans (MMN), PDA medium (Potato Dextrose Agar) or PDB (Potato Dextrose 
Broth), or others, according to nutrients requirements of the species). The strains are 
maintained on Petri dishes (9 cm diameter) containing the same media mentioned above at 
25°C in the dark and subcultured. After growth, the mycelium is recovered from the 
medium (Reis et al., 2011 and Carocho et al., 2012). 
As mentioned in the previous sections, mushrooms mycelia have demonstrated several 
bioactive properties, being used in the treatment, but mostly in the prevention of different 
diseases. Therefore, with the market requirements for these bioactive compounds, in vitro 
culture arises as the promissing alternative for their production. 
 
1.5 Objectives  
As mentioned before, mushrooms have been used for many years by different cultures as 
teas and nutritional foods, because of their special taste and texture. Agaricus bisporus and 
Pleurotus ostreatus are traditionally used as food, and accumulate a large variety of 
secondary metabolites, including phenolic compounds, polyketides, terpenes and steroids, 
with great bioactive potential. These species in particular have antioxidant, anti-
inflammatory and cytotoxic activities. Although many people appreciate mushrooms there 
are still some people that do not like its texture and flavor, being interesting to develop 
nutraceutical formulations that can be used per si or incorporated into other foods, 
providing bioactive properties. On the other hand, the in vitro production of mycelium can 
help to overcome difficulties associated with mushroom’s availability issues related to 
seasonality or adverse climatic conditions, for example. 
Therefore, this work had the main objective of developing nutraceutical formulations based 
on mycelium of Agaricus bisporus and Pleurotus ostreatus, and will include the following 
steps: 
1) Production of Agaricus bisporus and Pleurotus ostreatus mycelia to obtain extracts 
enriched in bioactive compounds namely, phenolic acids and mycosterols. Mycelia 
from each of the mushrooms were isolated in i) solid modified Melin-Norkrans 
medium (MMN) and liquid medium with the same composition, but without the 
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agar; ii) Potato Dextrose Agar (PDA) and Potato Dextrose Broth (PDB) media, 
after properly monitorization of the growth. 
2) Chemical characterization of the mycelia obtained in terms of phenolic acids 
(HPLC-DAD) and mycosterols (mainly ergosterol, HPLC-UV).  
3) Evaluation of their bioactive properties in particular antioxidant (free radicals 
scavenging activity, reducing power and lipid peroxidation inhibition), anti-
inflammatory (inhibition of NO production in mice macrophages) and cytotoxic 
(inhibition of the growth of different human tumor cell lines and of primary culture 
of non-tumor porcine liver cells). 
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CHAPTER 2. 
 
2. MATERIAL AND METHODOS 
 
2.1. Standards and reagents 
  
The solvents acetonitrile 99.9% and methanol were of high-performance liquid 
chromatography (HPLC) grade from Lab-Scan (Lisbon, Portugal). The standards of 
ergosterol, phenolic compounds (gallic, protocatechuic; p-hydroxybenzoic, p-coumaric, 
and cinnamic acids) and trolox (6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxylic acid) 
were purchased from Sigma (St. Louis, MO, USA). 2,2-Diphenyl-1-picrylhydrazyl 
(DPPH) was obtained from Alfa Aesar (Ward Hill, MA, USA). Dulbecco’s modified 
Eagle’s medium, hank’s balanced salt solution (HBSS), fetal bovine serum (FBS), L-
glutamine, trypsin-EDTA, penicillin/streptomycin solution (100 U/mL and 100 mg/ mL, 
respectively) were purchased from Gibco Invitrogen Life Technologies (Paisley, UK). 
Sulforhodamine B, trypan blue, trichloroacetic acid (TCA), lipopolysaccharide (LPS) and 
Tris were purchased from Sigma Chemical Co. (Saint Louis, MO, USA). RAW264.7 cells 
were purchased from ECACC (European Collection of Animal Cell Culture”, Salisburg, 
UK), and DMEM medium from HyClone (GE Healthcare Life Sciences, Logan, UT, 
USA). The Griess Reagent System Kit was purchased from Promega, and dexamethasone 
from Sigma. Thiamine, casamino acids, malt extract and agar were obtained from Panreac 
AppliChem (Barcelona, Spain). PDA and PDB were acquired from Oxoid microbiology 
products (Hampshire, United Kingdom). All other reagents and solvents were of analytical 
grade and obtained from common sources. Water was treated in a Milli-Q water 
purification system (TGI Pure Water Systems, Greenville, SC, USA). 
 
2.2. Samples and mycelium production  
Agaricus bisporus (J.E.Lange) Imbach was bought in the Clube Minipreço store in 
Braganca and Pleurotus ostreatus (Jacq. ex Fr.) P.Kumm. was acquired from a sterile 
wheat grain and boiled wheat straw cultivation bale in Bragança (Figure 5). 
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Figure 5: Pleurotus ostreatus in bales. 
 
Mycelia from both species were produced in the Biology and Biotechnology Laboratory of 
School of Agriculture of Bragança. 
Mycelia from each of the mushrooms were isolated from sporocarps in two solid and liquid 
media: 1) modified Melin-Norkrans solid medium (MMN) pH 6.6 (NaCl 0.025 g/L; 
(NH4)2HPO4 0.25 g/L, KH2PO4 0.509 g/L; FeCl3 0.0050 g/L, CaCl2 0.050 g/L, 
MgSO4.7H2O 0.15 g/L, thiamine 100.10 g/L, glucose 10 g/L, agar 20 g/L and tap water) 
(Marx, 1969 cited by Reis et al., 2011 and Carocho et al., 2012); 2) MMN liquid medium 
(prepared using the above reagents, without agar); 3) Potato Dextrose Agar solid medium 
(PDA) and 4) Potato Dextrose Broth liquid medium (PDB).  
The strains were maintained on Petri dishes (9 cm diameter) containing 10 mL of solid 
media and flasks with 20 mL of the same medium mentioned above at 25 °C in the dark 
and subcultured until mycelium covered most of the medium: approximately 21 days for P. 
ostreatus in solid medium and 42 days in liquid medium for A. bisporus, 56 days in solid 
and liquid medium. Radial growth measurements were registered every week from the 
inoculation time until the full growth of the mycelium (covering all available area) was 
obtained (Reis et al., 2011 and Carocho et al., 2012).  
After different growth time’s mycelia were recovered from both solid and liquid media, by 
scraping with a scalpel and sieved (particle size, 2 mm), respectively, in order to remove 
all medium residues (Figure 6).  
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Figure 6: Illustration of the mycelium production. 
 
Afterwards, all the samples (mycelium, culture medium and fruiting body) were placed in 
beakers and weighed separately to obtain fresh weight (fw) (Figure 7). Subsequently, the 
samples were frozen and lyophilized (freeze 4.5 FreeZone model 7750031, Labconco, 
Kansas, USA) to obtain the corresponding dry weight (dw). Finally, they were reduced to a 
fine powder (20 mesh).  
 
 
 
 
 
 
 
Figure 7: Illustration of mycelia separation from the medium. 
 
2.3. Preparation of the extracts  
 
Dried powder of each sample was placed in a beaker (≈2 g) and was extracted by magnetic 
stirring with methanol (30 mL) at 25°C and 150 rpm, for 1 h. The extract was separated 
  
Development of nutraceutical formulations based on mycelium of Pleurotus ostreatus and Agaricus bisporus 
 
25 
from the residue by filtration through Whatman paper No. 4 into a round flask. The residue 
was re-extracted once more under the same conditions and the filtrates were combined and 
concentrated with a rotary evaporated at ≈40°C (rotary evaporator, Büchi, Flawil 
Switzerland) (Figure 8). The extraction yield was calculated by measuring the extract 
weight in relation to the initial mass sample and stock solutions were prepared for the 
different biological assay measured. 
 
 
 
 
 
 
 
Figure 8: Illustration of the extraction procedure. 
 
2.4. Chemical characterization  
2.4.1. In phenolic acids  
Each sample was placed in a beaker (≈1g) and was extracted by magnetic stirring with 
methanol:water 80:20 (v/v) at 25°C and 150 rpm, for 1 h. The extract was separated from 
the residue by filtration through Whatman paper No. 4 to a round flask. The residue was 
re-extracted once more and the filtrate was rotary evaporated at ≈40°C to remove methanol 
(rotary evaporator, Büchi, Flawil Switzerland) (Reis et al., 2012). The aqueous phase was 
washed with n-hexane, and then submitted to a liquid-liquid extraction with diethyl ether 
(3 x 50 mL) and ethyl acetate (3 x 50 mL). The organic phases were evaporated at 30 ºC to 
dryness, redissolved in water:methanol (80:20), and filtered through a 0.22 µm disposable 
LC filter disk for HPLC analysis. 
The analysis was performed using a Shimadzu 20A series ultra-fast liquid chromatograph 
(UFLC, Shimadzu Coperation, Kyoto, Japan) as previously described by Reis et al., (2012) 
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(Figure 9). Separation was achieved on a Waters Spherisorb S3 ODS2 C18 column (3 µm, 
150 x 4.6 mm) thermostatted at 35ºC. The solvents used were: (A) 0.1% formic acid in 
water, (B) acetonitrile. The elution gradient established was 10% B to 15% B over 5 min, 
15–25% B over 5 min, 25–35% B over 10 min, isocratic 50% B for 10 min, and re-
equilibration of the column, using a flow rate of 0.5 mL/min. Detection was carried out in 
a photodiode array detector (PDA), using 280 nm as the preferred wavelength. The 
phenolic acids were quantified by comparison of the area of their peaks recorded at 280 nm 
with calibration curves (5-100 µg/mL) obtained from commercial standards of each 
compound: Protocatechuic acid (y = 164741x, R
2
=0.9996), p-hydroxybenzoic acid (y = 
113523x, R
2
=0.9993), p-coumaric acid (y = 433521x, R
2
=0.9981) and cinnamic acid (y = 
583527x, R
2
=0.9961). The results were expressed as µg per g of extract. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: HPLC-DAD equipment used in the analysis of phenolic acids. 
 
2.4.2. In ergosterol  
The extracts prepared above in section 2.3 were dissolved in methanol at a concentration of 
20 mg/mL and filtered through a 0.22 μm nylon disposable filter.  
Ergosterol analysis was performed by high performance liquid chromatography coupled to 
an ultraviolet detector (HPLC-UV) as previously described by Barreira et al., (2014) 
(Figure 10). The components of the HPLC-UV integrated system include a pump (Knauer, 
Smartline system 1000, Berlin, Germany), an UV detector (Knauer Smartline 2500), a 
degasser system (Smartline manager 5000) and an injector (autosampler) (AS-2057 Jasco, 
Easton, MD, USA). Chromatographic separation was performed with an Inertsil 100A 
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ODS-3 reversed-phase column (4.6×150 mm, 5 μm BGB Analytik AG, Boeckten, 
Switzerland) at 35 °C (7971R Grace oven). The mobile phase was acetonitrile/methanol 
(70:30, v/v), at a flow rate of 1 mL/min, and the injection volume was 20 μL. The detection 
was performed at 285 nm and data were analysed using Clarity 2.4 Software (DataApex). 
Ergosterol was quantified by comparing the area of its peak with the calibration curve 
obtained from a commercial standard. The results were expressed in mg per g of extract 
(Heleno et al., 2016). 
 
 
 
 
 
 
 
 
Figure 10: HPLC- UV system used in the analysis of ergosterol. 
 
2.5. Evaluation of bioactive properties  
 
2.5.1. Antioxidant activity  
The final extracts obtained in section 2.3, were dissolved in methanol obtaining stock 
solutions (20-80 mg/mL), then subjected to serial dilutions (40 and 0.01953 mg/mL), 
depending on the stock solutions and according to the assay. The in vitro antioxidant 
activity of the extracts was evaluated by performing four different assays: DPPH radical-
scavenging activity, reducing power, β-carotene bleaching inhibition and thiobarbituric 
acid reactive substances (TBARS) assay (Heleno et al., 2010). Trolox was used as positive 
control (Fernandes, 2010). 
2.5.1.1. DPPH radical scavenging activity 
This methodology was performed using a Microplate Reader ELX800 (Bio-Tek 
Instruments, Inc., Winooski, VT, USA). The deep violet chromogen DPPH radical is 
  
Development of nutraceutical formulations based on mycelium of Pleurotus ostreatus and Agaricus bisporus 
 
28 
reduced to slight yellow color in the presence of hydrogen donating antioxidants leading to 
the formation of non-radical form. The reaction mixture in each of the 96 wells consisted 
of different solutions of the extracts (30 µL) to which was added a methanolic solution 
(270 µL) containing DPPH radical scavenging (6 × 10-5 mol/L).  The mixture was allowed 
to stand for 60 min in the dark. The reduction of DPPH radical was determined by 
measuring the absorbance at 515 nm (Figure 11). The radical scavenging activity (RSA) 
was calculated as percentage of discoloration of DPPH solution using the formula: % RSA 
= [(ADPPH - AS) / ADPPH] × 100 where AS is the absorbance of the solution in the 
presence of a given extract concentration and ADPPH is the absorbance of DPPH solution. 
The extract concentration which leads to 50% radical scavenging activity (EC50) was 
calculated from the RSA percentage graph as a function of extract concentration. Trolox 
was used as standard (Fernandes, 2010). 
 
 
 
 
 
 
 
Figure 11: Microplate used in the evaluation of DPPH radical-scavenging activity. 
 
2.5.1.2. Reducing power 
This methodology was performed using the Microplate Reader, and is based on the ability 
to reduce yellow ferric form (Fe
3+
) to blue ferrous form (Fe
2+
) by the action of electron-
donating antioxidants (Pinela, 2012). 
Different concentrations of the extracts (0.5 mL) were mixed with sodium phosphate 
buffer (200 mmol/L, pH 6.6, 0.5 mL) with the addition of potassium ferricyanide (1% w/v 
0.5 ml) in eppendorf (2 mL) and incubated at 50 ºC for 20 min. After this incubation time 
0.5 mL of trichloroacetic acid 10% were placed in the eppendorf. The mixture (0.8 mL) 
was placed in 48 wells microplates with deionized water (0.8 mL) and ferric chloride 
(0.1% w/v, 0.16 mL) (Figure 12), measuring the absorbance at 690 nm. The concentration 
of extract that provides 0.5 absorbance (EC50) was calculated from the absorbance at 690 
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nm graph as a function of extract concentration. Trolox was used as standard (Fernandes, 
2010). 
 
 
 
 
 
 
Figure 12: Microplate used in the evaluation of reducing power. 
 
2.5.1.3. Inhibition of discoloration of β-carotene 
This assay is based on the capacity of the antioxidants to neutralize the linoleate free 
radical. This neutralization is detected by the discoloration of the yellowish color of 𝛽-
carotene. A solution of β-carotene was prepared by dissolving β-carotene (2 mg) in 
chloroform (10 mL). Two mililiters of this solution was transferred into a round bottom 
flask (100 ml). After the chloroform was removed at 40 ºC under vacuum, linoleic acid (40 
mg), Tween 80 emulsifier (400 mg), and distilled water (100 mL) were added to the flask 
with vigorous shaking. Aliquots (4.8 mL) of this emulsion were transferred into different 
test tubes containing different concentrations of the samples (0.2 mL). The tubes were 
shaken and incubated at 50 ºC in a water bath. As soon as the emulsion was added to each 
tube, the zero time absorbance was measured at 470 nm in a spectrophotometer 
(AnalytikJena, Jena, Germany) (Figure 13). β-Carotene bleaching inhibition was 
calculated using the following equation: (Abs after 2h of assay/initial Abs)  100. The 
extract concentration providing 50% of antioxidant activity (EC50) was calculated from the 
graph of β-carotene bleaching inhibition against extract concentrations. Trolox was used as 
a standard (Fernandes, 2010). 
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Figure 13: Test tubes used in the β‐carotene/linoleate assay. 
 
2.5.1.4. Inhibition of lipid peroxidation in the presence of thiobarbituric reactive 
substances (TBARS) 
TBARS is a colorimetric assay in which lipid peroxidation produces malondialdehyde 
(MDA) as secondary breakdown product, and reacts with the thiobarbituric acid (TBA) to 
form MDA-TBA complex with the production of a pink pigment (Ndhlala et al., 2010). 
Porcine (Sus scrofa) brains were obtained from official slaughtering animals, dissected, 
and homogenized with a Polytron in ice-cold Tris–HCl buffer (20 mM, pH 7.4) to produce 
a 1:2 (w/v) brain tissue homogenate, which was centrifuged at 3000g for 10 min. An 
aliquot (0.1 mL) of the supernatant was incubated with the different solution 
concentrations (0.2 mL) in the presence of FeSO4 (10 M; 0.1 mL) and ascorbic acid (0.1 
mM; 0.1 mL) at 37 ºC for 1 h. The reaction was stopped by the addition of trichloroacetic 
acid (28 % w/v, 0.5 mL), followed by thiobarbituric acid (TBA, 2 %, w/v, 0.38 mL), and 
the mixture was then heated at 80 ºC for 20 min. After centrifugation at 3000g for 10 min 
to remove the precipitated protein, the colour intensity of the malondialdehyde (MDA)-
TBA complex in the supernatant was measured by its absorbance at 532 nm (Figure 14).  
The inhibition ratio (%) was calculated using the following formula:  Inhibition ratio (%) = 
[(A – B)/A] × 100 %, where A and B were the absorbance of the control and the compound 
solution, respectively. The extract concentration providing 50% of antioxidant activity 
(EC50) was calculated from the graph of TBARS formation inhibition against extract 
concentrations. Trolox was used as a standard (Fernandes, 2010). 
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Figure 14: Test tubes used in the TBARS assay. 
 
2.5.2. Anti-inflammatory activity  
For the anti-inflammatory activity assay, the methanolic extracts (section 2.3) were 
dissolved in water at a concentrated of 10 mg/mL. For the various assays, the extracts were 
then submitted to further dilutions from 10 mg/mL to 0.16 mg/mL. Dexametazona was 
used as positive control (Taofiq, 2015). 
 
2.5.2.1. Cells treatment  
The mouse macrophage-like cell line RAW 264.7 was cultured in DMEM medium 
supplemented with 10% heat-inactivated foetal bovine serum, glutamine and antibiotics at 
37 °C under 5% CO2, in humidified air. For each experiment, cells were detached with a 
cell scraper. In the experiment cell density of 5×10
5
 cells/mL was used, and the proportion 
of dead cells was less than 5% according to the Trypan blue dye exclusion test. Cells were 
seeded in 96-well plates at 150,000 cells/well and allowed do attach to the plate overnight. 
Subsequently, cells were treated with the various concentrations of each extract for 1 h. 
Dexamethasone (50 µM) was used as a positive control for the experiment. The following 
step was the stimulation with LPS (1 µg/mL) for 18 h. The effect of all the tested samples 
in the absence of LPS was also evaluated, in order to observe if they induced changes in 
Nitric oxide (NO) basal levels. In negative controls, no LPS was added. Both extracts and 
LPS were dissolved in supplemented DMEM (Taofiq, 2015). 
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2.5.2.2. Nitric oxide determination 
 For the determination of nitric oxide, a Griess Reagent System kit was used, which 
contains sulphanilamide, N-(1-napthyl)ethylenediamine hydrochloride (NED) and nitrite 
solutions. A reference curve of nitrite (sodium nitrite 100 µM to 1.6 µM; 
y=0.0066x+0.1349; R
2
=0.9986) was prepared in a 96-well plate. The cell culture 
supernatant (100 µL) was transferred to the plate and mixed with sulphanilamide and NED 
solutions, 5-10 minutes each, at room temperature. The nitric oxide produced was 
determined by measuring the absorbance at 540 nm (microplate reader ELX800 Biotek), 
and by comparison with the standard calibration curve (Figure 15). The percentage of 
inhibition of the NO production was calculated, for each sample concentration, by the 
equation: [(Substrate concentration - Basal cells)/LPS – Basal cells] x100. The results were 
expressed as percent inhibition of NO production as compared to the negative control 
(100%) and EC50 values (concentration of sample that provides 50% inhibition of NO 
production) were also estimated (Taofiq, 2015). 
 
 
 
 
 
 
Figure 15: Microplate used in the evaluation of the NO assay. 
 
2.5.3. Cytotoxic activity  
For the cytotoxic activity assay, the methanolic extracts (section 2.3) were dissolved in 
water at a concentrated of 10 mg/mL. For the various assays, the extracts were then 
submitted to further dilutions from 10 mg/mL to 0.16 mg/mL. Ellipticine was used as 
positive control. 
 
2.5.3.1. For human tumor cell lines 
Four human tumor cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-
small cell lung cancer), HeLa (cervical carcinoma) and HepG2 (hepatocellular carcinoma). 
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Cells were routinely maintained as adherent cell cultures in RPMI-1640 medium 
containing 10% heat-inactivated FBS and 2 mM glutamine (MCF-7, NCI-H460, HepG2 
and HeLa cells) at 37 ºC, in a humidified air incubator containing 5% CO2. Each cell line 
was plated at an appropriate density (7.5×10
3
 cells/well for MCF-7 and NCI-H460 or 
1.0×10
4
 cells/well for HeLa and HepG2) in 96-well plates and allowed to attach for 24 h. 
Cells were then treated for 48 h with various extract concentrations. Following this 
incubation period, the adherent cells were fixed by adding cold 10% trichloroacetic acid 
(TCA, 100 μL) and incubated for 60 min at 4 ºC. Plates were then washed with deionised 
water and dried; sulforhodamine B solution (0.1% in 1% acetic acid, 100 μL, SRB) was 
then added to each plate well and incubated for 30 min at room temperature. Unbound 
SRB was removed by washing with 1% acetic acid. Plates were air-dried, the bound SRB 
was solubilised with 10 mM Tris (200 μL) and the absorbance was measured at 540 nm in 
the microplate reader mentioned above (Figure 16).  The results were expressed as GI50 
values (sample concentration that inhibited 50% of the net cell growth) in µg per mL 
(Barros et al., 2013).  
 
 
 
 
 
 
 
 
 
Figure 16: Microplate used in the evaluation of the cytotoxicity using human tumor cell lines. 
 
2.5.3.2. For non-tumor cell lines 
For evaluation of cytotoxicity in non-tumor cells, a cell culture from freshly harvested 
porcine liver and obtained from a local slaughterhouse was prepared according to the 
procedure described by Abreu and collaborators (2011), and referred by PLP2.  
The explants were placed in culture dishes with DMEM supplemented with fetal bovine 
serum (FBS) (10%), 2 mM nonessential amino acids, 100 U/mL penicillin and 100 μg/mL 
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streptomycin, and placed in the incubator at 37 ºC with a humidiﬁed atmosphere 
containing 5% CO2. Cultivation of the cells was continued with direct monitoring every 2-
3 days using a phase contrast microscope (Icon Eclipse Ts 100). The cells were transferred 
to a 96 well plate at a density of 1x10
4
 cells/well and cultured in DMEM with 10% FBS, 
100 U/mL penicillin and 100 µg/mL streptomycin. Cells were treated for 48h with 
different concentrations and sample made up SRB assay (Figure 17) as described above. 
The ellipticine was used as a positive control. The results were expressed in GI50 values 
(sample concentration that inhibited 50% of the net cell growth). 
 
 
 
 
 
 
 
Figure 17: Microplate used in the evaluation of the cytotoxicity in non-tumor cell lines. 
 
2.5.4. Statistical analysis 
For each culture component, fruiting body and fungal species, three independent samples 
were analysed. Data were expressed as mean ± standard deviation. All statistical tests were 
performed at a 5% significance level using IBM SPSS Statistics for Windows, version 
22.0. (IBM Corp., Armonk, NY, USA). 
The fulfilment of the one-way ANOVA requirements, specifically the normal distribution 
of the residuals (data not shown) and the homogeneity of variance, was tested by means of 
the Shapiro Wilk’s and the Levene’s tests, respectively. All dependent variables were 
compared using Tukey’s honestly significant difference (HSD) or Tamhane’s T2 multiple 
comparison tests, when homoscedasticity was verified or not, respectively. 
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CHAPTER 3. 
 
3. RESULTS AND DISCUSSION 
Mushrooms comprise a vast and yet largely untapped source of powerful new 
pharmaceutical products. In general, edible mushrooms are appreciated mainly for their 
nutritional value and most importantly for modern medicine. They represent an unlimited 
source of compounds with antioxidant, anti-inflamatory and cytotoxic potential, principally 
provided by different active substances, such as polysaccharides, lipids, peptides, sterols, 
or fiber (Ren et al., 2016). The great majority of the studies reporting the previous features 
are conducted on the fruiting body, but in this study, the mycelia, as well as the culture 
media utilized in different stages of mushroom production, also presented a good source of 
valuable compounds. This study also evaluated the bioactivity of these mushrooms, such 
as antioxidant, anti-inflammatory and cytotoxic activity. 
In antioxidant activity, non-enzymatic antioxidants such as β-carotene, ascorbic acid and 
α-tocopherol present in these mushrooms, may have an important role in the cellular 
response to oxidative stress, reducing reactive oxygen species (ROS), thus slowing the 
development of many chronic diseases as well as preventing lipid oxidation of food; these 
molecules have many applications as food additives, cosmetics, anti-aging and 
pharmaceutical products used in the treatment of chronic diseases related to oxidative 
stress (Fernandes, 2010). 
For the anti-inflammatory activity, NO is a signalling molecule that plays critical role in 
the pathogenesis of inflammation. Although physiological levels of NO are required for 
events such as vasodilation, angiogenesis, and neurotransmission, the overproduction of 
NO under pathological conditions can be a toxic and pro-inflammatory mediator that 
induces inflammation. Therefore, the ability of these mushrooms to inhibit NO production 
under inflammatory stimuli is relevant to the development of anti-inflammatory agents 
(Taofiq, 2015). 
We also evaluated the cytotoxic capacity of these mushrooms. Carcinogenesis is a process, 
which normally takes several years during which progressive genetic changes occur 
leading to malignant transformation. Cancer prevention is the best intervention in this 
process before invasive disease develops. Medicinal mushrooms have been used as 
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traditional medicine for the treatment and cancer prevention due to their important 
therapeutic properties (Ferreira et al., 2010 and Younis et al., 2014). 
 
3.1. Mycelia prodution  
 
In vitro production of mycelium can help to overcome difficulties associated with 
mushroom’s availability related to their seasonality or adverse climatic conditions, being 
an important methodology for continuous production of mycelia with uniform 
characteristics, contaminants free and of high quality for food and farmaceutical purposes. 
The establishment of P. ostreatus and A. bisporus in vitro allowed the evaluation of 
differential growth rates and chemical characterizations in two media culture and two 
different physical conditions (solid vs. liquid). 
After 7 days, the species P. ostreatus showed good growth on both media (PDA and 
MMNi solid medium). Mycelia were depigmented and cottony (Figure 18 C and D), and 
in PDA mycelia appeared as a thin layer (Figure 18E). The mycelia showed faster radial 
growth on PDA (Figure 20) and a higher biomass than on solid MMNi (fresh and dry 
weigth) (Figure 22). At the end of 3 weeks the entire plate was already covered with 
mycelia and the growth remained constant. 
However, in liquid PDB and MMNi mycelia started to growth at day 8, and presented the 
same caracteristics than in solid media. In four weeks some of the mycelia already covered 
the PDB medium plate, but in liquid MMNi they stoped to grow and didn't cover the plate, 
presenting half of the diametre of PDB (Figure 18 A and B). In PDB liquid medium the P. 
ostreatus mycelia had a higher growth rate (Figure 20) and biomass than in liquid MMNi 
(fresh and dry weigth) (Figure 21).  
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Figure 18: Pleurotus ostreatus mycelia cultivated in vitro, in both liquid (A-PDB and B- iMMN) and solid 
medium (C and E- PDA and D- iMMN). 
 
A. bisporus mycelia showed little growth in all media (PDA, PDB, solid and liquid 
MMNi). This species presented depigmented and rhizomorphic mycelia (Figure 19). 
This species started to grow in solid medium after 7 days. The mycelia grew in very small 
diameters and also grew into the culture medium, which hindered the removal of the 
mycelia; to solve this problem, mycelia were cultivated with cellophane paper (Figure 19 
J and K). The radial growth was faster in MMNi than in PDA (Figure 20), despite the 
similarities in the produced biomass (fresh and dry weigth) (Figure 21). They stopped 
growing within 6 weeks and didn't cover the plate, (Figure 19 H and I). 
In MMNi liquid medium they started to grow from day 14, but in PDB they started just 1 
week after MMNi. The mycelium appeared as a grain of quinoa in result of agitation to 
stimulate growth (Figure 19 F and G). The radial growth was faster in MMNi (Figure 20) 
and biomass was also higher than in PDB (fresh weigth), although in dry weigth PDB 
showed higher biomass (Figure 21). They stopped growing within 8 weeks and didn't 
cover the plate. (Figure 19). 
The main distinctive feature considering both radial growth patterns is that P. ostreatus 
exhibited a very fast initial growth in both media, although slower under liquid conditions 
reaching maximum radial growth after 14 days in solid medium while A. bisporus showed 
a slower and continuous growth rate along the 56 days period of culture, never reaching 
the complete top covering of the media. 
Although radial growth was higher in solid than in liquid media for both species, biomass 
production was higher in liquid than in solid media being similar in both media 
C D 
A B 
E 
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composition for A. bisporus but better in PDB for P. ostreatus and not very far from the 
biomass production in solid PDA medium. 
Under the culture conditions here studied we can consider better growth results in PDA 
and PDB media for P. ostreatus with similar biomass production. A. bisporus exhibit 
similar biomass production in both media formulations but significantly higher under 
liquid conditions. After these growth results, chemical characterization of the samples will 
determine the best growth conditions for our main purposes. 
 
 
 
 
 
 
 
 
 
Figure 19: Agaricus bisporus mycelia cultivated in vitro, in both liquid (F- PDB and G- iMMN) and solid 
medium (H- PDA and I- iMMN). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J                         K 
H                     I 
F                     G 
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A 
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Figure 20: Radial growth of A. bisporus (A) and P. ostreatus (B) mycelia cultivated in different culture 
media throughout time. 
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A
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Figure 21: Total biomass of A. bisporus (A) and P. ostreatus (B) mycelia. 
 
 
3.2. Chemical characterization of the extracts 
 
Mushrooms have a lot of bioactive compounds including phenolic acids and ergosterol, 
also related to their nutraceutical potential (Barros et al., 2009 and Ferreira et al., 2009). 
Nutraceuticals present in mushrooms have been related to their antioxidant, anti-
inflammatory and cytotoxic activities (Fernandes et al., 2015). A. bisporus and P.ostreatus 
are sources of these compounds. 
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Mycelia, culture media (liquid culture media in which mycelia were dissolved) and fruiting 
bodies were compared in terms of bioactive compounds and properties.  
Phenolic acids and ergosterol contents are presented in Table 10, while the 
chromatographic profiles of these compounds are shown in Figure 22 and 23. The highest 
content of ergosterol was found in the fruiting body of A. bisporus (17.4 ± 0.1 mg/g 
extract); it was not found in the culture medium. However, for P. ostreatus it was the 
mycelium cultivated in the PDB medium that showed higher quantity (18.56 ± 0.07 mg/g 
extract). The presence of ergosterol in these mushrooms was previously described by 
Villares and collaborators (2014). No ergosterol was also found in the PDB culture 
medium. 
In general and comparing mycelia, A. bisporus gave lower content of ergosterol (ranging 
from iMMN solid - 2.87 ± 0.04 to PDB - 3.71 ± 0.04 mg/g extract) than P. ostreatus 
(ranging from iMMN liquid - 9.08 ± 0.03 to PDB - 18.56 ± 0.07 mg/g extract). But in 
fruiting bodies, it was A. bisporus (17.4 ± 0.1 mg/g extract) that showed higher content of 
ergosterol in comparison with P. ostreatus (9.7 ± 0.2 mg/g extract).  
Among the phenolic acids, p-hydroxybenzoic and cinnamic acids were the major 
compounds in both mushrooms and in all samples. p-Hydroxybenzoic acid in mycelium 
grown in PDA reached quantities nearly five times higher in A. bisporus (1030 ± 59 g/g 
extract) than in P. ostreatus (188 ± 34 g/g extract). P. ostreatus fruiting body showed also 
high levels of this phenolic acid. 
The phenolics compounds obtained in the present study are the same than those reported in 
literature for A. bisporus and P. ostreatus (unless the vanillic acid that could not be found 
in the present study) (Barros et al., 2009). Cinnamic acid was found in higher amounts in 
P. ostreatus mycelium grown on PDB (438 ± 2 g/g extract). 
Regarding fruiting bodies, A. bisporus and P. ostreatus showed higher levels of p-
hydroxybenzoic acid (129 ± 3 and 463 ± 11 μg/g extract, respectively) than of the other 
phenolic acids identified.  
A. bisporus showed more quantity of cinnamic acid in the mycelium produced in PDA 
culture medium (134 ± 1mg/g extract), while P. ostreatus have higer concentration in the 
mycelium produced in PDB (438 ± 2 mg/g extract). 
Protocatechuic acid was not found in A. bisporus like in previous studies (Reis et al., 2012) 
and in P. ostreatus it was only found in the fruiting body (217 ± 16 mg/g extract) and in 
the mycelium produced in PDA (272 ± 7 mg/g extract). In previous studies protocatechuic 
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acid in P. ostreatus was found only in the fruiting body (Reis et al., 2012 and Muszyńska 
et al., 2013). 
A. bisporus gave higher levels of p-coumaric acid (10.4 ± 0.2 to 241 ± 9 mg/g extract) 
when compared with P. ostreatus. This acid was present in all samples of A. bisporus, 
unless in the culture media. But for P. ostreatus, it only appeared in the fruiting body (165 
± 2 mg/g extract) and in the mycelium produced in iMMN solid medium (17 ± 1 mg/g 
extract). 
The differences observed between the studied samples and the values reported in literature 
are related with their different harvesting years and geographic locations that comprise 
diverse climatic conditions, which have influence on chemical compostion (Barros et al., 
2009; Reis et al., 2012 and Muszyńska et al., 2013). For example, Reis et al. (2012) 
described the presence of another phenolic acid (gallic acid) in the same mushroom species 
but from cultivated origin (Reis et al., 2012). 
The phenolic compounds and ergosterol contents (and not profiles) cannot be directly 
compared to previous studies because we expressed results in mg/g extract, and other 
literature expressed the resulst in dry weight basis (mg/g dw) (Barros et al., 2009; Reis et 
al., 2012; Muszyńska et al., 2013 and Barreira et al., and Villares et al., 2014). 
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Figure 22: Chromatographic profiles of phenolic compounds of A. bispous (Mycelium: 1- p-
hydroxybenzoic acid, 2- p-coumaric acid, 3- cinnamic acid) and P. ostreatus (Fruiting body: 1- 
protocatechuic acid, 2- p-hydroxybenzoic acid, 3- p-coumaric acid, 4- cinnamic acid).  
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Figure 23: Chromatographic profiles of ergosterol of A. bisporus (Fruiting body and Mycelium: 1- 
ergosterol).  
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Table 10: Ergosterol (mg/g extract) and phenolic acids (μg/g extract) content in the mycelia and culture media of A. bisporus and P. ostreatus. The values corresponding to 
the fruiting body of both mushrooms (edible samples) are also presented. Values are given as mean±standard deviation. 
 Ergosterol Protocatechuic acid p-Hydroxybenzoic acid p-Coumaric acid Cinnamic acid 
Agaricus bisporus 
Fruiting body (edible) 17.4±0.1 nd 129±3 17.9±0.7  15.3±0.1 
iMMN liquid 
Mycelium 3.27±0.05
b
 nd 12.5±0.1
d
 10.4±0.2
b
 9.0±0.1
c
 
Culture medium Nd nd 363±21
b
 Nd 14±3
c
 
PDB 
Mycelium 3.71±0.04
a
 nd 416±13
b
 50±1
b
 27±1
b
 
Culture medium Nd nd 56±2
c
 Nd 7.87±0.02
d
 
iMMN solid Mycelium 2.87±0.04
c
 nd 10±1
d
 24±1
c
 2.4±0.1
e
 
PDA Mycelium 3.69±0.01
a
 nd 1030±59
a
 241±9
a
 134±1
a
 
p-values (n = 54) 
Homoscedasticity
1
 0.143 - 0.052 0.029 0.072 
1-way ANOVA
2
 <0.001 - <0.001 <0.001 <0.001 
 
Pleurotus ostreatus 
Fruiting body (edible) 9.7±0.2 217±16 463±11 165±2 142.8±0.4 
iMMN liquid 
Mycelium 9.08±0.03
d
 nd 38.2±0.5
d
 Nd 114.8±0.3
c
 
Culture medium 0.013±0.001
e
 nd 235±8
ab
 Nd 90±1
d
 
PDB 
Mycelium 18.56±0.07
a
 nd 266±4
a
 Nd 438±2
a
 
Culture medium Nd nd  125±3
c
 Nd 167±3
b
 
iMMN solid Mycelium 12.13±0.03
c
 nd 77.5±0.5
cd
 17±1 93±1
d
 
PDA Mycelium 16.0±0.3
b
 272±7 188±34
b
 Nd 75±5
e
 
p-value (n = 54) 
Homoscedasticity
1
 0.045 0.023 0.048 0.023 0.165 
1-way ANOVA
2
 <0.001 <0.001 <0.001 <0.001 <0.001 
1Homoscedasticity among culture components was tested by the Levene test: homoscedasticity, p>0.05; heteroscedasticity, p<0.05. 2p<0.05 indicates that the mean value of at least one component differs from the 
others (in this case, multiple comparison tests were performed). For each culture component, means within a column with different letters differ significantly (p<0.05).
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3.3. Antioxidant activity 
 
The organisms are equipped against damage caused by free radicals with several defense 
mechanisms acting in different ways. As indicated, the antioxidants are natural molecules 
which prevent the uncontrolled formation of free radicals and ROS or inhibit their reaction 
with biological structures, interrupting the chain reaction and forming radicals having low 
reactivity which are easily removed from the body (Falcão, 2008 and Fernandes, 2010).  
Maintaining balance between the production of free radicals and antioxidants cell defenses 
are an essential condition for the normal functioning of the body (Ferreira et al., 2009). 
However, a balance between ROS and antioxidant defenses can be destabilized either by 
overproduction of ROS or the loss of the antioxidant defenses of cells. This imbalance is 
known as oxidative stress and, in this case, the excess ROS oxidize and can damage lipids, 
proteins and DNA of the cell, leading to alteration and inhibiting its normal function 
(Ferreira et al., 2009). Ascorbic acid, α-tocopherol, β-carotene and other carotenoids, such 
as lycopene, and phenolic compounds are examples of antioxidants obtained from food. 
Mushrooms are a major source of these molecules (Fernandes, 2010). 
The results obtained for each of the performed antioxidant activity assays, expressed as 
EC50 values, are shown in Table 11. Figure 24 illustrates the test tubes or microplates in 
the preformed assays.  
 
 
 
 
 
 
 
 
 
Figure 24: Test tubes and microplates used in the antioxidante activity assays. 
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Regarding fruiting bodies, the highest activity was obtained in the TBARS formation 
inhibition assay (A. bispous: 0.09±0.01 mg/mL; P. ostreatus: 0.090±0.002 mg/mL), 
followed by β-carotene bleaching inhibition (in the case of P. ostreatus: 0.7 ± 0.1 mg/mL) 
end reducing power (in the case of A. bispous: 0.81 ± 0.01 mg/mL). The lowest activity 
was observed in DPPH radicals scavenging activity assay (P. ostreatus: 3.2 ± 0.1 mg/mL; 
A. bisporus: 3.27 ± 0.03 mg/mL).  
In general, the values obtained for A. bisporus (for example: Reducing power - 0.81 ± 0.01 
mg/mL and TBARS - 0.09 ± 0.01 mg/mL) and P. ostreatus (for example: β-carotene - 0.7 
± 0.1 mg/mL and TBARS- 0.09 ± 0.002 mg/mL) fruiting bodies represent higher 
antioxidant activity than that reported previously (for example: A. bisporus: Reducing 
power - 1.80 ± 0.03 mg/mL and TBARS - 2.9 ± 0.5 mg/mL; P. ostreatus:  β-carotene - 2.7 
± 0.2 mg/mL and TBARS - 2.6 ± 0.9 mg/mL), (except for DPPH in A. bisporus) (Reis et 
al., 2012b). Also, for mycelia, the antioxidant activity of these species was higher (for 
example: A. bisporus: DPPH - 10.1 ± 0.03 mg/mL; P. ostreatus: DPPH - 17.1 ± 0.4 
mg/mL) (except for β-carotene bleaching inhibition assay in A. bisporus) than that reported 
by those authors (for example: A. bisporus: DPPH - 40 ± 2 mg/mL; P. ostreatus: DPPH - 
29 ± 6 mg/mL) (Reis et al., 2012b).   
In this context, phenolic acids are described as being important compounds with 
antioxidant activity in mushrooms due to the presence of OH groups in their chemical 
structures that are known for their ability to scavenge free radicals (Heleno et al., 2012a).  
Regarding P. ostreatus, the DPPH scavenging activity and β-carotene bleaching inhibition 
(3.2 ± 0.1 and 0.7 ± 0.1 mg/mL, respectively) was higher than those previously reported 
(5.11 ± 0.65 and 440 ± 43 mg/mL, respectively (Silva, 2015). A. bisporus also showed 
higher radical scavenging activity (3.27 ± 0.03 mg/mL) and reducing power (0.81±0.01 
mg/mL) than a similar sample previously reported in literature (9.61 ± 0.07mg/mL and 
3.63 ± 0.02 mg/mL, respectively) (Martins et al., 2012). 
Considering the main purpose of this work, it was very interesting to discover that the 
antioxidant activity measured in the mycelia and in culture media was very close (in some 
cases better) to that verified in the fruiting bodies, emphasizing the high potential of these 
in vitro culture produced fungal components. In the case of the culture media, these results 
have an increased interest, since those components are usually considered as by-products 
of mushroom’s cultivation. Furthermore, the differences among the same culture media, 
after being used to grow each one of the mushroom species, indicate that the measured 
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antioxidant activity is in fact due to the mycelium grown in it, and not to the culture media 
components. Therefore, some compounds responsible for the antioxidant activity are 
released to the culture medium; while others are kept in the mycelium. 
The culture media of P. ostreatus gave better results than the same components of A. 
bisporus. P. ostreatus in PDB culture medium showed higher β-carotene bleaching 
inhibition, TBARS formation inhibition and reducing power, while A. bisporus in  MMN 
culture medium gave better results in DPPH scavenging activity and reducing power 
assays. Otherwise, A. bisporus mycelia produced in liquid medium MMN gave worst 
results than P. ostreatus in TBARS formation inhibition and β-carotene bleaching 
inhibition assays.  
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Table 11: Antioxidant activity (EC50 values, mg/mL) of the mycelia and culture media of A. bisporus and P. ostreatus. The values corresponding to the 
fruiting body of both mushrooms (edible samples) are also presented. Values are given as mean±standard deviation. 
 DPPH scavenging activity Reducing power β-carotene bleaching inhibition TBARS formation inhibition 
Agaricus bisporus 
Fruiting body (edible) 3.27±0.03 0.81±0.01 2.2±0.1 0.09±0.01 
iMMN liquid 
Mycelium 17.7.±0.3
b
 1.98±0.01
c
 4.4±0.2
ab
 0.7±0.1
b
 
Culture médium 18.2±0.5
b
 2.25±0.02
a
 4.7±0.1
ab
 1.4±0.1
a
 
PDB 
Mycelium 14.7±0.1
c
 1.23±0.01
e
 4.2±0.4
b
 0.19±0.01
cd
 
Culture médium 21.8±0.6
a
 2.11±0.02
b
 4.9±0.1
a
 0.36±0.02
c
 
iMMN solid Mycelium 13.31±0.1
d
 1.58±0.01
d
 4.5±0.1
ab
 0.22±0.003
cd
 
PDA Mycelium 10.1±0.03
e
 0.46±0.01
f
 4.2±0.1
b
 0.13±0.003
d
 
p-value (n = 54) 
Homoscedasticity
1
 0.005 0.174 0.045 0.002 
1-way ANOVA
2
 <0.001 <0.001 <0.001 <0.001 
Pleurotus ostreatus 
Fruiting body (edible) 3.2±0.1 1.79±0.01 0.7±0.1 0.09±0.002 
iMMN liquid 
Mycelium 56.9±0.6
a
 4.08±0.06
a
 4.6±0.2
a
 0.220±0.001
a
 
Culture médium 57.3±0.9
a
 3.66±0.01
b
 2.1±0.1
b
 0.22±0.01
a
 
PDB 
Mycelium 16.87±0.09
d
 1.85±0.01
c
 0.70±0.06
d
 0.04±0.0004
d
 
Culture médium 32.3±0.6
c
 1.9±0.1
c
 1.5±0.1
c
 0.17±0.01
b
 
iMMN solid Mycelium 52.4±1.4
b
 3.96±0.04ª 2.4±0.1
b
 0.18±0.01
b
 
PDA Mycelium 17.1±0.4
d
 1.94±0.01
c
 0.92±0.01
d
 0.080±0.001
c
 
p-value (n = 54) 
Homoscedasticity
1
 0.059 0.108 0.016 0.003 
1-way ANOVA
2
 <0.001 <0.001 <0.001 <0.001 
Trolox  41.68±0.28 41.43±1.27 18.21±1.12 22.84±0.74 
1Homoscedasticity among culture components was tested by the Levene test: homoscedasticity, p>0.05; heteroscedasticity, p<0.05. 2p<0.05 indicates that the mean value of at least one component differs from the 
others (in this case, multiple comparison tests were performed). For each culture component, means within a column with different letters differ significantly (p<0.05).  
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3.4. Anti-inflammatory activity 
 
The ability of both mushroom species to modulate the production of the inflammatory 
mediator NO (nitric oxide) was evaluated in RAW 264.7 macrophages by pre-treating cells 
with various concentrations of their methanolic extracts (Table 12).  
LPS (lipopolysaccharide) is a cell wall component of Gram-negative bacteria, and plays a 
central role in the pathogenesis of several diseases (Taofiq, 2015). Macrophages are the 
main components of the innate immune system, and have essential regulation functions in 
several immunopathological conditions during the inflammatory process (Yoon et al., 
2009).  
When macrophages are exposed to LPS, the LPS binds to receptors that activate several 
signalling pathways that intern result in activation of NF-κB. When the NF-κB signalling 
pathway is activated, macrophages secrete NO and pro-inflammatory cytokines. Hence, 
natural agents that regulate the production of various cytokines and suppress the 
overproduction of NO may have protective roles in inflammation-related diseases such as 
cancer, diabetes and cardiovascular disease (Nam and Yuan et al., 2006). Endotoxin LPS is 
able to induce the production of mediators like NO, pro-inflammatory cytokines (besides 
inhibiting anti-inflammatory cytokines) and tumor necrosis factor in macrophages. 
Thereby, macrophages stimulated by LPS have been widely used for anti-inflammatory 
activities evaluation in vitro (García-Lafuente et al., 2009). In addition, due to reproducible 
response of RAW264.7 macrophages to LPS, this cell line has been widely used for 
inflammatory research (Huang & Ho, 2010 and Taofiq, 2015). 
Although phenolic acids were the compounds identified in the studied species, their 
content did not correlate with the inhibitory capacity of the extracts, which suggests that 
the contribution of these kinds of compounds to the anti-inflammatory activity is not 
relevant.  
However, cinnamic acid derivatives, such as caffeic acid, have been previously described 
to down-regulate the production of proinflammatory cytokines in CACO-2 cells (Moro et 
al., 2012). By contrast, in other studies, cinnamic acid derivatives, such as caffeic acid, 
chlorogenic acid, ferulic acid and p-hydroxybenzoic acid, from an ethanolic plant extract, 
did not affect NO production in LPS-stimulated RAW 264.7 macrophages (Yu et al., 
2009). 
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According to the obtained results none of the species showed anti-inflammatory activity 
(Figura 25). But, in previous studies presented by Moro et al. (2012) in methanolic 
extracts, A. bisporus showed an inhibition of NO production by 30% at 0.5 mg/mL and P. 
ostreatus 15% at 0.5 mg/mL. These authors explain that, pyrogallol that is only present in 
extracts of A. bisporus, Cantharellus cibarius Fr., Craterellus cornucopioides (L.) Pers.  
and Lactarius deliciosus (L. ex Fr.) S.F.Gray cited by Palacios et al., (2011), may be partly 
responsible for the anti-inflammatory activity. In the same way, pyrogallol from the 
medicinal plant Emblica officinalis, has been identified as one of the active compounds 
responsible for the anti-inflammatory effect of Emblica extracts in bronchial epithelial 
cells (Nicolis et al., 2008). Synergisms between pyrogallol and other active compounds 
present in the extracts, such as flavonoids or cinnamic acid derivatives, could explain the 
differences in activity among the extracts studied by the mentioned authors. 
According to the results reported by Taofiq (2015) for ethanolic extracts (EC50 values), P. 
ostreatus (96 ± 1 mg/mL) showed better results than A. bisporus (190 ± 6 mg/mL).  
 
 
 
 
 
 
 
 
Figure 25: Microplates used in anti-inflammatory activity assay. 
 
3.5. Cytotoxic activity 
 
The cytotoxic activity of A. bisporus and P. ostreatus extracts against the four carcinoma 
cell lines (MCF-7, NCI-H460, HeLa and HepG2) and against a porcine liver primary cells 
culture (PLP2) is shown in Table 12. 
As already stated, mushrooms are sources of several of powerful new pharmaceutical 
products. In particular, and most importantly for modern medicine, represent a powerful 
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source of compounds with potential antitumor and immunostimulating properties. Many of 
these compounds have been used in the treatment of many health problems, including 
cancer (Wasser, 2002). 
Only the extracts prepared from P. ostreatus samples showed some activity against the 
four tumor cell lines (Figure 26). A. bisporus extracts could not inhibit these cell lines (up 
to the maximum assayed concentration: 400 μg/mL extract), ie, this species did not show 
any antitumor potential. 
 
 
 
 
 
 
 
 
Figure 26: Microplate used in the evaluation of the cytotoxicity. 
 
The extracts of P. ostreatus samples showed similar behavior in all cell lines (GI50 values 
varying from 224 ± 14 to 375.0 ± 0.1 μg/mL). In this species, the fruiting body showed 
activity only for NCI-H460 (GI50 = 306 ± 27 mg/mL). The mycelium produced in liquid 
medium MMN presented the highest cytotoxic effect against HepG2. All mycelia showed 
some activity in tumor cell lines, but none of the culture medium showed activity.   
A previous work reported activities of A. bisporus and P. ostreatus mycelia (methanol 
extract) against HepG2 (54.9 ± 2.4 and 56.3 ± 2.5 mg/mL, respectively) and HeLa (38.7 ± 
1.9 and 52.2 ± 2.5 mg/mL, respectively) (Younis et al., 2014).  
P. ostreatus samples that showed the highest cytotoxic activity gave also the highest 
content in phenolic acids and ergosterol. 
The extracts from A. bisporus and P. ostreatus did not exhibit a toxic effect on the primary 
cell line. Interestingly, none of the assayed culture components inhibited the growth of 
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PLP2 cell line, which constitutes a good indicator of the lack of toxicity of the mycelia and 
culture media of both mushroom species in non-tumor cell lines. 
Mushroom extracts can be used in combination with traditional chemotherapy or used as 
alternative sources for adjuvant cancer therapy, as some of these extracts have no adverse 
effects and activate the cells of the immune system. The bioactive compounds of 
mushrooms may complement classical cancer therapy and counter the side-effects of 
cancer, such as nausea, bone marrow suppression, anemia, and lowered resistance (Barros 
et al., 2007 and Patel et al., 2012). 
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Table 12: Cytotoxic (GI50 values. μg/mL) and anti-inflammatory activity (EC50 values. μg/mL) of the mycelia and culture media of A. bisporus and P. ostreatus. The 
values corresponding to the fruiting body of both mushrooms (edible samples) are also presented. Values are given as mean±standard deviation. 
 MCF-7 NCI-H460 HeLa HepG2 PLP2 RAW264.7 
Agaricus bisporus 
Fruiting body (edible) >400 >400 >400 >400 >400 >400 
iMMN liquid 
Mycelium >400 >400 >400 >400 >400 >400 
Culture médium >400 >400 >400 >400 >400 >400 
PDB 
Mycelium >400 >400 >400 >400 >400 >400 
Culture médium >400 >400 >400 >400 >400 >400 
iMMN solid Mycelium >400 >400 >400 >400 >400 >400 
PDA Mycelium >400 >400 >400 >400 >400 >400 
p-value (n = 54) 
Homoscedasticity - - - - - - 
1-way ANOVA - - - - - - 
Pleurotus ostreatus 
Fruiting body (edible) >400 306±27 >400 >400 >400 >400 
iMMN liquid 
Mycelium 239±18
b
 329±17
a
 286±23
b
 224±14
c
 >400 >400 
Culture médium >400 >400 >400 >400 >400 >400 
PDB 
Mycelium >400 >400 >400 375.0±0.1
a
 >400 >400 
Culture médium >400 >400 >400 >400 >400 >400 
iMMN solid Mycelium 327±15
a
 >400
a
 >400 312±21
b
 >400 >400 
PDA Mycelium 330±28
a
 271±19
b
 338±1
a
 280±24
b
 >400 >400 
p-value (n = 54) 
Homoscedasticity 0.262 0.118 0.054 0.293 - - 
1-way ANOVA <0.001 <0.001 <0.001 <0.001 - - 
Dexamethaxone  - - - - - 15.70±1.1 
Ellipticine  0.91±0.04 1.03±0.09 1.91±0.06 1.14±0.21 3.22±0.067 - 
1Homoscedasticity among culture components was tested by the Levene test: homoscedasticity, p>0.05; heteroscedasticity, p<0.05. 2p<0.05 indicates that the mean value of at least one component differs from the 
others (in this case, multiple comparison tests were performed). For each culture component, means within a column with different letters differ significantly (p<0.05). 
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CHAPTER 4. 
 
4. CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
This study was designed to develop nutraceutical formulations based on mycelium of 
Agaricus bisporus and Pleurotus ostreatus, as potential alternative sources of bioactive 
compounds or as ingredients to be used in applications with antioxidant, anti-inflammatory 
or cytotoxic activities. 
According to the obtained results, we have demonstrated that the growth rate of mycelia 
depends on the culture media. Potato dextrose agar (PDA) media was the best one for P. 
ostreatus, while incomplete Melin-Norkans medium (iMMN) solid media proved to be the 
best one for A. bisporus. Growth diameter rate is not correlated with the biomass of 
mycelium; for instance, radial growth was higher in solid than in liquid media for both 
species, but biomass production was higher in liquid than in solid media. 
We obtained better growth results in PDA and PDB media for P. ostreatus with similar 
biomass production, and A. bisporus exhibited similar biomass production in both media 
formulations but significantly higher under liquid conditions. 
For the chemical analysis, the methanolic extracts showed several phenolic acids (p- 
hydroxybenzoic acid, p-coumaric acid and protocatechuic acid), a related compound 
(cinnamic acid) and ergosterol, which have been suggested to play an important role in 
antioxidant, anti-inflammatory and antitumor activities. 
In general, P. ostreatus mycelia showed higher contents of ergosterol (9.08-18.56 mg/g 
extract). Cinnamic acid (75-438 μg/g extract) and p-hydroxybenzoic acid (463 μg/g 
extract) were also more abundant in the fruiting body of this species, but the mycelia of A. 
bisporus produced on PDA presented a higher amount of p-hydroxybenzoic acid (1030 
μg/g extract). 
Summing up, A. bisporus mycelia produced in PDA gave higher amounts of phenolic acids 
and ergosterol, but P. ostreatus had better contents of ergosterol, p-hydroxybenzoic acid 
and cinnamic acid in PDB and protocatechuic acid in PDA. 
Likewise, the antioxidant activity was also higher among the P. ostreatus components, 
with the highest activity being obtained with the TBARS formation inhibition assay (EC50 
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= 0.04 mg/mL). A. bisporus, showed better results of antioxidant properties in mycelia 
produced in PDA, and P. ostreatus had better results in PDB. 
Extracts of A. bisporus did not show anti-inflammatory and cytotoxic activities up to the 
maximum assayed concentrations, contrarily to the observed for the mycelia of P. 
ostreatus, which showed some cytotoxicity, but did also not shown anti-inflammatory 
activity. 
P. ostreatus mycelia showed cytotoxicity in tumor cell lines what did not happen with the 
fruiting body (except in NCI-H460, GI50 = 306 μg/mL). The highest activity was found 
against HepG2 (GI50 = 224 μg/mL). Therefore, it is difficult to assess which compounds 
are relevant for anti-inflammatory or antitumor activities of the studied sample. 
Furthermore, none of the species showed toxicity against non-tumor cells.  
The culture components showed differentiated activity, which should be considered 
together with the growth rate and biomass yielded for each mushroom. 
On the basis of obtaining unmodified natural products or nutraceutical formulations 
exhibiting antioxidant, anti-inflammatory and cytotoxic properties, to be used as food 
supplements or industrial applications that bring health benefits, the in vitro culture can be 
a great ally to obtain these bioactive compounds from fruiting body. That's why, science 
tools (genomic, proteomic and metabolomic) should be used to help further in vitro culture 
in order to obtain the most promising bioactive molecules to develop novel pharmaceutical 
products and nutraceuticals formulations with an overall positive impact on human health, 
but keeping environmental preservation.  
The safety of these compounds has been showed by the absence of hepatotoxicity in 
porcine liver primary cells (PLP2), but in vivo models should be considered in future steps. 
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